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The Versatility of Ether-Bridged Cycloadducts Towards the Synthesis of Complex 
Natural Products 
 
Harold Deshaun Cooper, PhD 
University of Connecticut, 2013 
 
 
 The presence of a heterocyclic moiety can be observed in many of today’s 
bioactive natural products.  One of the most commonly observed is furan, an aromatic 
five-membered ring containing an oxygen atom. Furan is a simple compound, yet 
versatile enough to be used as a synthetic synthon leading to complex structures such as 
the antioxidant Phelligridin G and the antibacterial agent Platensimycin. In the former, it 
is spiro-fused to the five-membered carbocycle of the 6-5-5 tricyclic domain while in the 
latter it makes up the ether-bridged cycloadduct of the hydrophobic cage.    
Conventionally, furan can undergo cycloadditions in the presence of reactive dienophiles 
via the Diels-Alder reaction to form oxabicyclic synthons.      
A strategy for the synthesis of the embedded spirocyclic core of phelligridin G 
from a 2-phenylfuran system was developed.  Finding a suitable dienophile compatible 
with this biphenyl ring was a daunting task; however, we successfully obtained the 
oxabicyclo[2.2.1]heptadiene intermediate upon surveying a plethora of available 
dienophiles. Exposure of the strained ring system to the Grubbs’ 2nd generation 
ruthenium-based catalyst facilitated a domino ring-opening metathesis/ring-closing 
metathesis (ROM/RCM) to give a spiroannulated furan. Further evaluation showed the 
highly reactive tetrachlorocyclopropene was a compatible dienophile leading to the 
formation of spiro-fused pyran ring structures through a related metathesis approach. 
Recently, we have developed a novel and expedient route towards the tetracyclic 
caged domain of platensimycin using an oxabicyclo[3.2.1]octadiene building block.   
Within our methodology a late-stage intermediate has been established from the [4+3] 
cycloaddition of a substituted furan with tetrabromocyclopropene along with an 
intramolecular γ–alkylation to form the seco-cage of this hydrophobic region.  It has been 
postulated that structural modifications could help improve its poor pharmacokinetic 
profile while retaining potent bioactivity. Utilizing this furan-based route has led to the 
synthesis of several novel analogues that will be evaluated for their antimicrobial activity 
against methicillin-resistant Staphylococcus aureus (MRSA).  We have assembled a 
unique derivative in which the cyclohexanone moiety has been replaced with the more 
constricted cyclopentanone ring.  A second series of analogues synthesized have the C-
ring completely removed from the caged domain and manipulation of the ketone 
functionality was evaluated. 
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CHAPTER 1 
INTRODUCTION 
 
Exploitation of Heterocyclic Chemistry: Studies on Furan Synthons 
The ability to control functional group interchanges in an organic compound is 
one of the most valuable tools for a synthetic chemist.  This is a unique and practical skill 
set that allows us to assemble a variety of natural products, which have led to some of the 
world’s most recognized therapeutic agents.  The intricate structural design of many 
natural products allows the chemist to be creative and innovative when developing a 
synthetic strategy. A highly functionalized intermediate can be used to build the most 
complex organic molecules.  A single chemical transformation, utilizing commercially 
available starting materials such as furan, can lead to a considerable increase in molecular 
complexity via a single step based upon new carbon-carbon bond formations.  In 2001, 
Wright published a review discussing how using the heterocycle furan as a synthetic 
synthon toward complex polycyclic ring systems.1  There can be a variety of polycyclic 
systems synthesized if an efficient method can be developed to synthesize polycyclic 
furans.  Being that furan is so versatile it can undergo numerous transformations such as 
oxidations, reductions, or cycloadditions (Figure 1.1). 
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Figure 1.1 Synthetic equivalences of furan  
 
 
Oxabicyclic Ethers 
Furan Diels-Alder 
The Diels-Alder reaction is one of the more recognizable approaches to give way 
to oxabicyclic synthons. Formation of these bridged cycloadduct intermediates can take a 
simple heterocyclic compound and transform it into something more structurally complex 
in a single reaction.  These oxabicyclic synthons also allow a great deal of stereo-and 
chemoselective transformations to occur within the molecule to add more complexity.  
The combination of furan and a reactive dienophile by this cycloaddition approach, one 
of the most powerful and useful strategies to form functionalized aromatic rings, can lead 
to the desired oxabicyclic systems (Figure 1.2).  The versatile structures can be changed 
to cyclohexenes by cleavage of the oxygen bridge or to a substituted tetrahydrofuran via 
cleavage of the two-carbon bridge. Additionally, the oxygenated diene can undergo [4+3] 
cycloadditions with oxyallyl cations to give various oxabicyclo[3.2.1]octane derivatives.  
These intermediates can also serve as precursors to tetrahydrofurans, as well as pyrans 
and cycloheptenes by cleavage of one of the three unique bridges.  
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Figure1.2 Utility of oxabicyclic synthons 
 
 
Diels-Alder Cycloaddition [4+2]  
 Since its discovery in the first half of the 20th century the Diels-Alder 
cycloaddition reaction has proved to be a compelling tool in the construction of today’s 
most complicated organic molecules.  Addition of highly reactive dienophiles such as 
alkenes and alkynes tend to be resourceful for heterocyclic compounds.  As previously 
mentioned, the heterocycle furan can undergo various transformations via Diels-Alder 
reaction; however, it has been found that certain substitutions at the C-2 or C-5 position 
can hinder ether-bridged adduct formations.  Presently there exist a number of published 
articles on the use of furan in thermal cycloadditions; therefore, in this section the [4+2] 
and [4+3] cycloadditions will be briefly examined. 
  In 2011, Ogawa and co-workers have successfully synthesized 3-
hydroxphthalates with the assistance of Lewis acid catalysts.2  Routes to these derivatives 
proceed through a Diels-Alder cycloaddition accompanied by catalyst leading to a ring-
opening aromatization in a one pot synthesis.  Isolation of the cycloadducts showed that 
dimethyl acetylenedicarboxylate (DMAD) was a suitable dienophile for substituted furan 
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systems.  Based on the fluctuation of desired product yields, it was found IrCl3.3H2O 
catalyst influenced the reactivity rate more than FeCl3 or Cu(OTf)2 catalyst.  Another 
important factor was the type of substitution present in the C2 position.  Presence of an 
electron-donating group such as methyl exhibited good to excellent yields.  2-
Phenylfuran 1a produced the desired aromatic compound in good yields; however, the 
oxabicyclic intermediate 3a was only 10% isolatable.  Addition of electron-withdrawing 
groups such as nitro, cyano, or trifluoromethyl groups to the 2-arylfurans dramatically 
reduced the reactivity rates (Scheme 1.1).          
 
Scheme 1.1 Diels-Alder reactions with 2-phenylfuran systems leading to 3-hydroxyphthalates  
   
Higher-Order Cycloaddition [4+3]  
Successful syntheses leading to an abundant number of complex natural products 
have been reported by Wright and co-workers employing [4+3] cycloadditions.  In the 
Wright group, they have focused on forming bicyclo[3.2.1]octadienes between the 
heterodiene furan and tetrahalocyclopropenes.3  The Wright group has utilized the 
synthesis of oxabicyclic intermediates via cyclocondensation of di-substituted furan and 
tetrabromocyclopropene. It has been known for some time that tetrahalocyclopropenes 
can be directly converted to a series of analogous bicyclo[3.2.1]octadiene derivatives by 
reaction with various dienes.  It was first reported by Tobey and West in 1968 that 
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tetrachloro- and tetrabromocyclopropene were highly reactive dienophiles and underwent 
Diels-Alder reactions under thermal conditions (Scheme 1.2).4  Once the cyclopropyl 
norbornene 7 is derived, a spontaneous rearrangement occurs via migration of the 
halogen atom to form oxabicyclo intermediate 8. A silver-promoted hydrolysis of the 
tetrahalide leads to generation of the substituted enones 9 in a 2:1 ratio.  This attack of the 
cation by the water molecule is sterically influenced.  The less hindered terminus is 
preferentially attacked due to the shielding of the allyl system by the bridgehead alkyl 
group.  
 
Scheme 1.2 Development of the oxabicyclo[3.2.1]octadiene nucleus by halogen migration 
 
Wright et al. show that these highly functionalized tetrahalobicyclo[3.2.1]octadienes  can 
be amended with good selectivities; however, studies conducted have shown that certain 
reactive nucleophiles were unsuccessful in the addition to these bridged synthons.  
Additions occur by 1,2 addition or 1,4 additions to form intermediates that can be applied 
to the synthesis of natural products containing highly functionalized seven-membered 
rings.    
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Techniques towards Spiroannulations 
 A common, yet challenging structural motif found in many natural products are 
the spirocycles.  These compounds consist of two rings joined together sharing only a 
single carbon.  Over the years there has been a considerable amount of attention 
dedicated to these types of organic compounds.  Natural spirocycles are of great interest 
to chemist because of their potential use as a novel therapeutic in addition to their 
distinctive designs found in nature.  In this section we will focus on a series of routes 
developed to easily construct not only spiro-fused cycloalkanes, but the more exceptional 
spiro-fused heterocycles. 
 Kumar and co-workers have utilized a Claisen rearrangement toward the 
spiroannulation of cyclopentane rings that serve as precursors to the acorone and 
isoacorone sesquiterpene ketones.5  Cyclohexane-1,4-dione underwent a sequence of 
steps to give allyl alcohol 14 in good yield by way of a controlled Wittig-Horner-
Emmons reaction, protection of the ketone, and regiochemical reduction of 13 
(Scheme1.3).  Claisen rearrangement was crucial for the generation of the quaternary 
center required in the formation of a spiro ring system.  This process was thermally 
activated in one pot with a catalytic amount of propionic acid and 2-methoxypropene led 
to 16.  After ozonolysis of the terminal alkene 14, spiroenone 17 was furnished via an 
intramolecular aldol condensation facilitated by potassium hydroxide base.  Further 
conversion transformed 17 into the desired spirodienone 18 through the prochiral 
precursor 16 leading to the chiral acorones.  This methodology served as a convenient 
pathway to form the functionalized spiro[4.5]decane.  Furthermore, they performed 
studies on the annulation of spiro-fused cyclopentanes leading to spiro-enones 23a-d. 
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Scheme 1.3 Spiroannulation of cyclopentane rings towards the synthesis of sesquiterpene ketones    
 
Trost and co-workers have utilized a stereoselective approach to spirocycles 
through ring contractions.6   Compound 26 was synthesized by the intercalation of 28 
with β-keto sulfones 31 as a key intermediate to the spiro-fused molecules.  Allowing the 
β-keto sulfone to reflux for 3 hours in Lewis acid condition has led to the desired 
spirocyclic isomers 26 only after quenching with ethanol.  It was determined that the 
transformation followed a pinacol type of rearrangement with the removal of the sulfone 
group in acidic media (Scheme 1.4).   
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Scheme 1.4 Ring constriction to spiro-fused cyclopentenones 
 
The rate of rearrangement depends on the size of the ring.  Thermal conditions play a 
vital role to get the appropriate product from intermediate 25.  In order to achieve 
complete isomerization of the β,γ isomer 25 to the α,β isomer 26 it was necessary to use 
refluxing methylene chloride, which is considered the slow step in the reaction.  At lower 
temperatures they noticed after quenching the mixture only cyclized ketone 33 could be 
isolated (Scheme 1.5).  Controlling the alkylation of the keto-sulfone is correlated to 
controlling the stereochemistry of 24.  This cyclocontraction-spiroannulation route has 
opened new dimensions to the usefulness of sulfones in total synthesis due to the 
sensitivity of this functional group to Lewis acid ionization.      
 
Scheme 1.5 Ring expansion leading to unsuccessful spiroannulations  
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 In 2005, Undheim et al. created an efficient way to make bisarene type 
compounds by way of forming rigid spirane bridged sandwich like polycyclic systems.7 
There were assembled different ring sizes because they could control the rigidness of the 
structure with the larger ring systems being more flexible than the smaller ones. 
Annulations to form five-membered spirocycles had been previously reported via 
alkylation of 2-oxocyclopentanecarboxylate followed by an acid catalyst with p-
toluenesulfonic acid to form spiro[4.4]nonane-1,6  36 (Scheme 1.6).  This route was not 
as successful with the larger six-membered carbocycles.  Further investigations led to a 
new route to generate spiro[4.5]decane-1,6-dione 39 with the assistance of a rhodium-
catalyzed intramolecular acylation to the acetal 38.  The solvent used along with the 
presence of too much catalyst exhibited some decarbonylation; however, it was found 
reducing the amount of [Rh(COD)Cl]2 by half while running the reaction neat increased 
the yield of 39 to 90%.  Ring closing metathesis (RCM), which is a more traditional 
method, was found to be another procedure used to form these spirocycles.  Addition of 
Ru(II) catalyst to diene 40 after heating 3 hours led to the larger spiro[5.5]undecan-1,7-
dione 41 intermediate.  With these highly functionalized intermediates, further 
transformations were employed resulting in the stereoselective α,α'-cis, cis-diaryl 
spiranes 44a and 44b. 
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Scheme 1.6 Preparation of spirane bridged systems towards bisarenes 
   
     As previously mentioned, a direct route to polycyclic ring closures is by using the 
Ru(II)-catalyzed RCM which has been utilized by Kotha and co-workers for the 
spiroannulation of barbituric acid derivatives.8  Besides the pharmaceutical value of 
barbituric aid derivatives, they can also be useful building blocks to various complex 
supramolecular structures.  The strategies towards these potential novel analogs begin 
with the available carbonyls 45 and 48 as starting materials.   Each substrate was exposed 
to two different approaches.  The first would require the RCM of dialkenylated malonate 
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precursors 46.  A second approach required presence of an active methylene group which 
is then alkylated by an electrophilic terminal vinyl moiety to give 49 which undergoes 
RCM to form spiro-fused diketone 50 (Scheme 1.7).  
Scheme 1.7 Strategies towards the spiro-annulated compounds 
 
Spiro-compound 56 is obtained upon a successful RCM reaction initiated by the 1st and 
2nd generation Grubbs’ catalysts.  Attempts to synthesize spiro-fused heterocycle 52 were 
unsuccessful following the first strategy utilizing diethyl malonate 51. Malonate 55 
formed spiro-annulated diester 56 upon exposure to Grubbs 1st generation catalyst at 
room temperature in high yields; however, the hindered nature of the spirocyclic system 
failed to undergo condensation with urea.  Hence all reaction efforts were focused on the 
alternate strategy which validates to be a better yielding route to a series of spiro-
annulated barbituric acid derivatives (Scheme 1.8).  
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Scheme 1.8 Ring closing metathesis as a key step to synthesizing barbituric derivatives and 
analogs 
 
 A nontraditional methodology towards spirocyclic molecules have been 
investigated by Swenton and coworkers using electrochemistry.9  These new carbon-
carbon bonds were prepared on phenol substrates containing an electron rich olefinic 
substituent to identify the competing reactions within the molecule.  Studies on substrate 
65 showed that the yield of anodic cyclization was affected by the location of the double 
bond (Scheme1.9).  This electron rich intermediate was assembled by combining the 
ketone 62 and 63 followed by acid-catalyzed dehydration of 64.  Anodic oxidation of the 
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vinyl aromatic system gave spiro-fused 66 in good yield.  The addition of the methyl 
group forces the vinyl linker closer to the 4-position of the oxidized phenol; therefore, the 
intramolecular cyclization is much faster.  The rate of reaction not only depends on the 
placement of the olefin, but the conditions as well.  It was found that spiro-annulation on 
4-(2-alkenylphenyl)-phenols and the trimethylsilyl derivatives performed best in neutral 
or mildly basic conditions.  Furthermore, electrochemistry can be applied to substrates 
containing acid or base-sensitive functional groups.  
 
Scheme 1.9 The intramolecular anodic electrooxidative cyclization of phenols. 
 
  Mechanistically, there are two potential pathways annulation can occur within the 
biphenyl substrate.  The spiroannulation of 67 could be achieved by reaction of the 
alkene with the phenoxonium intermediate.  Trapping of the carbocation 69 with 
methanol completed the reaction.  An alternative route could be a one electron loss from 
the substrate followed by nucleophilic attack of the phenol on the oxidized styrene double 
bond to generate radical 72.  A second electron loss, quenching with methanol, and 
finally dehydrogenation generates the spiro-fused 70 (Scheme 1.10). 
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Scheme 1.10 Mechanism of Spiroannulated phenol. 
 
Routes to Oxaspirocycles  
Application of Electroxidative Cyclizations 
 The use of electroxidative cyclization (EOC) has been a useful tool in the 
synthesis of an array of small molecules. Many five, six, and seven-membered 
cyclizations have been easily achieved for some of the more complex bioactive motifs.  
Within the past several years there has been an increase of publications involving 
electrochemical methodology, especially en route to some of these more complex natural 
products.  Researchers in these groups have developed efficient routes to a variety of 
uniquely designed products found in nature including oxaspirocyclic compounds.   
Although it is far from being a routine technique, electrochemical reactions have 
gained a lot of interest within the organic synthesis community.  This experimental 
procedure usually can be identified as a last resort method once all other options have 
been attempted.  Many researchers have found electrolysis to be straightforward, 
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environmentally friendly, and a quick path to some very interesting organic compounds. 
These reactions can be either oxidations or reductions with the reactions being comprised 
of the substrate, electrodes, electrolyte, solvent, and various additives.  EOCs are 
tolerable of most functional groups and are applied to the synthesis of complex natural 
products. They follow the general principle of radical-cation formation via 
electroxidation, followed by an intramolecular trapping of a nucleophile that takes place 
in organic solvents such as methanol and 2-propanol; these protic solvents in turn attack 
the substrates nucleophilically due to the reactions taking place at the surface of the 
electrodes.          
Bernhardt et al. displayed that a direct approach to the 2-oxaspiro[4.5]decan-1-
one structural motif can be constructed by 6-π electrocyclization.10  Previously it had 
been observed that the most ideal way to form spiro 74 was through the Diels-Alder 
reaction of the lactone and a given reactive diene.  A late-stage cyclization of the six-
membered ring is an unusual approach, but it proved to be a successful pathway to spiro-
fused lactone 76 using the appended cyclohexene ring 75 (Scheme 1.11).   
 
Scheme 1.11 Electrocyclization to the 2-oxospiro[4.5]decan-1-one structural motif. 
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Olefin Metathesis Reaction 
 The olefin metathesis was initially discovered in the mid-1950s and has been a 
reliable resource to redistribute carbon-carbon double bonds in organic synthesis.  There 
was not always the availability of an effective catalyst until the 1980’s.  Some major 
issues with these earlier reactive catalysts are their sensitivity to oxygen and moisture in 
the air in addition to having poor functional group tolerance. It was not until the 
development of the ruthenium-based catalyst did they overcome these issues.  Ruthenium 
catalyst reacted preferentially with olefins in the presence of aldehydes, amides, alcohols, 
and even carboxylic acids.  The most recognized are the Grubbs 1st and 2nd generation 
catalysts 77 and 78, which led to an eruption in olefin metathesis chemistry in the 
synthetic world (Figure 1.3).  They have been utilized in a variety of reactions such as 
ring opening metathesis polymerization (ROMP), ring-closing metathesis (RCM), cross 
metathesis (CM), ring-opening metathesis/cross metathesis (ROM/CM), and even tandem 
reactions.  
 
Figure 1.3 Ruthenium-based catalysts for metathesis 
 
In 1999, Harrity and co-workers demonstrated an efficient way for the preparation 
of functionalized spirocyclic systems using Grubbs’s 1st generation catalyst.11  The spiro-
compounds were made under mild reaction conditions.  Oxaspiro 80 was assembled 
using a tandem ring closing metathesis reaction on tetraalkene 79 (Scheme 1.12).  
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Although it was found the 5-membered ring formation was dominant, there was a 7-
membered ring closure observed as well.  The selectivity of the tandem metathesis can be 
controlled by the amount of catalyst introduced into the environment.   The oxaspiro 82 
decomposed rapidly upon treatment with catalytic TsOH at ambient temperatures.   Acid 
catalyzed techniques were found to be harmful to the functionalized [4.4]-spiroacetals, 
hence they were subjected to a neutral metal catalyzed cyclization condition for 
completion.    
 
Scheme 1.12 Tandem ring-closing metathesis (RCM) of tetraalkenes  
 
Palladium Catalyzed Reactions towards Spiro-fused Furans 
 Bäckvall et al. explored the use of palladium as a means to form oxaspiro 
compounds.12,13  Over the years this research group has focused on an approach to control 
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the stereochemistry for either cis or trans 1,4-addition across 1,3-diene double bonds. 
Studies on the alcohols 87 and 91 have been an excellent template for palladium-
catalyzed oxidations due to the competing factors present in the cyclohexadiene ring. 
Within these compounds lies the possibility of aromatization and/or Diels-Alder addition 
to the existing diene.  The presence of a base, such as lithium carbonate, has shown to 
help expedite the intramolecular cyclization while a slow addition of the oxidant 
benzoquinone suppresses aromatization of the starting material (Scheme 1.13).  
Stereochemistry of the final oxaspiro product was heavily influenced by the salt added to 
the system.  This route has led to the construction of flexible spiro-fused furano building 
blocks leading to the natural product theaspirone 90.    
 
Scheme 1.13 The oxaspirocyclization of conjugated dienes via palladium-catalyzed 
oxidations. 
 
    A different approach to the aforementioned theaspirone family of spiroethers was 
investigated in 2000.  Realizing other intramolecular oxaspirocyclizations already exist, 
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Young and co-workers employ the assistance of Amberlyst-15 as an alternative catalyst 
to the previously published technique with a palladium-catalyst.14  Young et al. have 
reported a sufficient step by step route with secondary allylic alcohol 96.  Treatment of 
the allylic alcohols with the Amberlyst-15-catalyst proceeds through SN2 annulations to 
produce 1-oxaspiro[4.4]non-6-enes 97 (Scheme 1.14).  Limitations have been observed 
with the spirocyclization of tertiary allylic alcohols because 1-oxaspiro[4.4]non-6-ene 
and 6-oxaspiro[4.5]dec-1-ene systems allylic cannot be derived by treating the 
corresponding 2-cyclopentenone with methyl lithium.  After five steps theaspirone 98 has 
been constructed in good yield at 67% using SN2 oxaspirocyclizations.     
 
Scheme 1.14 The oxaspirocyclization of sterically hindered allylic alcohols toward 
theaspirone 
  
Robinson Annelation toward Spirofused Pyrans 
 Pfalz and co-workers were able to successfully expand upon the synthesis of 
oxaspirocyclic compounds leading to pyran derivatives.15 The spiro-fused pyran 103 was 
obtained via Robinson annelation upon treatment of 4-carboxaldehyde 102 with methyl 
vinyl ketone and removal of the double bond by catalytic hydrogenation (Scheme 1.15).  
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This method has been useful for a variety of heterocyclic compounds leading to a diverse 
group of 3-heterospiro[5.5]undecan-9-ones.  A novel method to increase the yield of the 
starting aldehyde 102 is currently in the works by this group. 
 
Scheme 1.15 Preparation of 3-Heterospiro[5.5]undecan-9-one from tetrahydropyran. 
        
Natural Products and Targets 
Within our group we have focused our research efforts on the synthesis of small 
molecules derived from natural materials that exhibit biological activity.  The motivation 
for making these molecules have led to the following: 1) development of new methods 
starting with oxabicyclic ring systems to produce building blocks for total synthesis 2) 
innovative ways to form complex fused ring systems and analog library from natural 
products previously synthesized within our research group, and 3) combination of 
traditional and nontraditional ring annulations toward heterocyclic compounds.  Our 
inspiration for these novel routes has been attributed to the natural products phelligridin 
G 104 and platensimycin 105 (Figure 1.4). The overall structural framework and 
important biological activity (antioxidant and antibacterial) have made these compounds 
attractive targets for our research group.  As medicinal chemists, it is our goal to use our 
training as synthetic chemists to design new compounds in order to study their 
bioactivity. 
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Figure 1.4 Natural Product Targets 
 
Antioxidants in Drug Discovery 
Many scientific experts in the field of free radical and antioxidant biology have 
seemingly joined the effort, pioneered by preventive medicine practitioners, to stimulate 
disease prevention and health promotion research.  Antioxidants are molecules capable of 
inhibiting the oxidation of other molecules.  Oxygen-derived free radicals have been 
identified as the source to the pathology of more than 100 diseases.16 These free radicals 
can be highly reactive and toxic causing oxidative stress in the human body. Controlling 
these chemical reactions in the body can prevent the development of unwanted free 
radicals, which can initiate chain reactions leading to cell damage or apoptosis. This 
phenomenon contributes to the development of a wide variety of diseases from 
Alzheimer’s disease, Parkinson’s, rheumatoid arthritis, cancer, and the pathologies 
caused by diabetes.  Currently, there are only a few drugs approved by the FDA used to 
treat these diseases.  Memantine (Namenda) is an n-methyl-D-aspartate (NMDA) 
receptor agonist used in the treatment of Alzheimer’s by regulating the activity of 
glutamate.17 Succinobucol, a newly synthesized antioxidant, has shown promise in the 
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prevention and treatment of diabetes.18 Doxorubicin (Adriamycin) is a drug administered 
intravenously used to treat a variety of carcinomas during chemotherapy.19  
Research over the past twenty years has led to the notion that antioxidant nutrients 
are significantly associated with disease prevention (i.e. cardiovascular and 
cerebrovascular disease, various carcinomas and age related disorders).16 Some of the 
more familiar antioxidants include vitamins, vitamin-forming compounds such as 
carotenoids, or manufactured in dietary supplements.20,21 Synthetic antioxidants are an 
area of research actively being pursued to find new and more efficient ways to enhance 
antioxidant defenses.  Scavenging of these free radicals can occur in the intestines, brain, 
muscles, or tissues by the addition of these potential synthetic antioxidants.  Being that 
small molecule therapeutics derived from synthetic antioxidants requires long-term 
administration and exhibit adverse side-effects, chemists continue the investigation of 
novel agents for these diseases.   
Phelligridin G 
A significant amount of the medicines today are derived from natural products 
that can be found in various plant species throughout nature as well as algae or fungi. 
Natural products are a significant source of new drugs, especially in the anticancer and 
antihypertensive therapeutic areas.22 There is now increasing evidence with experimental 
animals that regular feeding of powdered medicinal mushrooms can have a cancer 
prevention effect, demonstrating both high antitumor activity and restriction of tumor 
metastasis.23 A potent family of medicinal fungi are the polysaccharides derived from 
Phellinus igniarius and Agrocybe cylindracea.24   
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Secondary metabolites produced by the fruiting bodies of mushrooms frequently 
display a variety of unique structures and interesting biological activities.  Phelligridins 
D, E, and G are derived from the fruiting body of the fungus P. igniarius, a member of 
the Polyporaceae family (Figure 1.5).  The highly oxygenated fungal metabolites are 
indigenous of the Dandong district in Liaoning province, China. The fruiting body of P. 
igniarius has been long used for the treatment of fester, bellyache and bloody gonorrhea 
as a traditional Chinese medicine.25  Of these three derivatives phelligridin G has shown 
the better antioxidant activity inhibiting rat liver microsomal lipid peroxidation 
(IC50=3.86µM), and moderate selective cytotoxic activities against human ovarian cancer 
cell line (A2780) and colon cancer cell lines (HCT-8).26  Based on the potential of 
phelligridin G as an anti-cancer agent along with its unique and synthetically challenging 
spirofused-furanone, we set out to develop a rapid and efficient synthetic route to the core 
domain of the natural product.  
 
Figure 3.5 Structural Derivatives of Phellinus igniarius 
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Antibacterial Drug Development 
Over the past decade, there has been an increased need for new antibacterial 
agents due to the resistance of existing therapeutics.  Fatty acid synthase by bacterial type 
II fatty acid synthase (FASII) can be carried out by a series of discrete enzymes.  There 
are important structural differences in the enzymes of bacterial systems that allow the 
development of potential inhibitors to target these systems.  Most of the FASII enzymes 
are essential for bacterial viability which makes them suitable targets for antibacterial 
drug discovery.  There have been a number of scientific reviews published discussing the 
inhibition of bacterial fatty acid synthesis.27  Natural products are known to target the 
elongation condensing enzymes step in the fatty acid biosynthesis pathway which makes 
them desirable targets for therapeutics.  Some of these natural compounds include 
cerulenin, thiolactomycin (TLM), phomallenic acids, platensimycin, and most recently 
fasamycin.   
Over two decades ago they identified the first inhibitor cerulenin, which 
selectively targets FabF/FabB and covalently bonds to the cysteine in the active site of 
the enzyme.  Cerulenin is an antifungal antibiotic with minimal inhibitory concentration 
(MIC) of 64-128µg/mL and inhibitory concentration (IC50) of 1.5µg/mL against S. 
aureus.
28
  During this time thiolactimycin was also discovered and found to be a selective 
dual inhibitor of FabH and FabF/B while binding to malonate in the active site. This 
reversible inhibitor showed MIC and IC50 values of 64-128 µg/mL and 13 µg/mL 
respectively against the gram positive S. aureus. In 2002, Townsend and co-workers 
developed an asymmetric route towards this modest antibacterial agent.29  In their 
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synthetic route they used amino acids as chiral building blocks to assemble the natural 
product thiolactone.   
Studies on phomallenic acids A, B, and C showed good antibacterial and FASII 
activities against S. aureus, H. influenza, B. subtilis, and E.coli.  Of the three analogs 
phomallenic C exhibited the most potent activity against these strains with significantly 
lower IC50 values than A or B.  Utilizing a whole-cell screening approach such as those 
performed by Young et al. proved that the inhibition of fatty acid synthesis enzymes is 
responsible for inhibiting growth of bacteria leading to the discovery of potential 
antibacterial drugs.28    
Platensimycin: Background 
Scientist at Merck and Co., Inc. discovered two promising natural products 
platensimycin and platencin produced by Steptomyces platensis in 2006.  These novel 
antibiotics showed promising antibacterial activity along with no observed toxicity.  
Platensimycin is effective against methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant enterococci.  With such promise as a useful drug against antibiotic-
resistant gram-positive bacterial pathogens, there is a concern with its pharmacokinetic 
properties.  Platensimycin inhibits the elongation-condensing enzyme FabF, but platencin 
can be seen as a dual inhibitor of FabF and FabH.  MIC values of platensimycin against 
gram-positive bacteria are some of the best observed at 0.1-0.32µg/mL.30  Comparison 
between the two derivatives found that platensimycin exhibited poor activity against 
FabH, while platencin was 15 fold less active against the Fab F enzyme.  Both derivatives 
provide a solution to fighting antibiotic-resistant bacteria, but due to poor 
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pharmacokinetics reported by researchers they have yet to enter clinical trials.  This has 
led to the rationale and increased interest for analog development via modifications of its 
molecular structure.  Platensimycin has two distinct structural domains: the hydrophilic 
dihydroxybenzoic acid and the hydrophobic tetracyclic enone moieties linked together by 
an amide bond (Figure 1.4).  
 
Survey of Structural Analogues 
Within the past 5 years there have been a number of research groups that have 
synthesized structural analogs of the parent compound platensimycin.  In 2009, scientist 
at Merck developed an analog program based on the alteration of the tetracyclic ketolide 
domain.  While performing initial studies based on the structure-activity relationship, 
they found that chemically modifying the enone moiety could have a major impact on the 
potency of molecule.  They were able to develop a library of nine different analogs that 
inhibit the FabF enzyme as well as show some antibacterial activity.   
Researchers at Merck Laboratories created an extensive analog program to help 
guide their future structural designs based upon structure-activity relationship (SAR) and 
the pharmacophore of platensimycin.31  Shen and co-workers believed that the poor 
pharmacokinetics of platensimycin is possibly due to the enone moiety of the compound. 
The natural products high clearance in vivo can be attributed to this component acting as 
an electrophile; therefore, modifying this group can potentially reduce the undesirable 
properties without reducing the antibacterial activity.  The first set of analogs 108 a-d 
required saturation of the double bond of the six-membered enone ring (Scheme 1.16).  
The olefin did not show any direct interactions with the FabF enzyme; however, they 
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noticed a 4-8 fold loss of antibacterial activity against the wild type S. aureus.  The 
reason for such a loss is a direct result of the minor repositioning of the ketone  as well as 
the benzoic acid moiety which occurs because the platensimycin changes from the boat 
conformation to the chair conformation with the absence of the double bond in the 
cyclohexenone ring.  The binding pocket of platensimycin is quite rigid and cannot 
contain substantial conformational changes.  A cyclopropyl group was added via the 
Corey-Chaykovsky cyclopropanation to give cyclopropyl analog 108d which proved to 
be 4 fold more active than the saturated compound 108a.   
 
Scheme 1.16 Synthetic route towards tetracyclic derivatives 
 
R Compound 
 
S. aureus MIC values 
(µg/mL) 
IC50 sa FASII (µg/mL) 
105 
 
0.5 0.5 
108a 
 
2 2 
108b 
 
4 13 
108c 
 
4 4 
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108d 
 
1 9.5 
108e 
 
16 10.5 
108f 
 
>64 75.3 
108g 
 
4 2.4 
108h 
 
>64 73.6 
 
108i 
 
>64 >200 
 
A way to replace the electrophilic enone was by developing a series of fused heterocyclic 
analogs.   They utilized pyrazole and isoxazole hoping the heteroatoms could mimic the 
missing enone carbonyl oxygen, while maintaining the sp2 character of the ketone α-
carbon in the natural product.  Generation of heterocycles 108e and 108f resulted in 
analogs with much weaker activity.  The presence of a heteroatom to replace the α-carbon 
of the enone was also investigated by this research group.  Preparation of lactone 108h 
and lactam 108i were achieved, yet exhibiting the worse activity of all the analogs 
synthesized.   
It was found through SAR that the conformation of the enone moiety is very important in 
the positioning of the ketone carbonyl group to maximize its interaction with A309 of 
FabF.  Minimal conformational changes such as in analog 108b by simple methylation of 
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the β-position of the enone proved to be the most active in the FabF enzyme of all the 
compounds in the library.  Those analogs such as 108d  and 108g having a similar 
conformation to platensimycin in addition to the presence of the ketone group seemed to 
be more favorable as future analog designs. 
 Nicolaou and co-workers performed some of the first reported synthetic strategies 
in analog development as well as the SAR data of platensimycin by implementing 
varying degrees of molecular complexity.32   Based upon X-ray crystallographic data of 
platensimycin in complex with a mutant version of FabF enzyme showed two distinct 
domains for binding within the target.  These findings have led the Nicolaou group to 
create two series of analogues by modifying both the hydrophilic benzoic acid domain 
and lipophilic cage domain (Figure 1.6).  Changes to the polar aromatic group can assist 
in determining the importance of the substitution pattern for biological activity leading to 
analogue series I.  Secondly the analogue II series probed adjustments made to the 
tetracyclic cage moiety to note any biological changes.  
 
Figure 1.6 The two distinctive domains of platensimycin  
  
The synthesis of analogue series I required the use of platensic acid 109 which 
was the key intermediate toward their published asymmetric approach to platensimycin.33  
The aniline derivatives were obtained through a late-stage divergence from commercially 
available carboxylic acids.  Coupling of platensic acid 109 with the synthesized amines 
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were accomplished by a HATU-mediated amide coupling (Scheme 1.17).  The results of 
these structural modifications negatively impacted the biological profile of the natural 
product.  The benzoic acid analogue showing the best MIC values against MRSA was 
platensic acid 109 at 37-58µm/mL.  
 
Scheme 1.17 Synthesis of aniline derivatives 
 
  Analogue series II was more strategic due to the fact they wanted to assemble 
complex cage mimics, in addition structurally similar to the parent natural product (Table 
1.1).  A cyclohexenone derivative was prepared sequentially by allylation and 
methylation in the presence of base, a chemoselective cross-metathesis to give 
corresponding E/Z isomers of pinacol boronates which were subjected to oxidative 
cleavage to give an aldehyde.  A key Pinnick oxidation of the carbonyl led to racemates 
of methyl esters that could be easily separated using a chiral column.  Final amide 
coupling with the aniline fragment and deprotections gave the cage analogues 114-117.   
Surprisingly, this derivative exhibited some antibiotic activity without regards to the 
lower amount of structural complexity with MIC values of 3.5-4.3µg/mL against MRSA.  
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Table 1.1 
 Compound MRSA VREF 
105 
 
1.1-2.2 1.1-1.2 
114 
 
1.3-1.8 1.3-1.8 
115 
 
3.5-4.4 6.5-8.6 
116 
 
8.0-10 >80 
117 
 
17-20 >85 
110 
 
>85 >85 
111 
 
>85 >85 
112 
 
>82 >82 
113 
 
>73 >73 
 
109 
 
37-58 >58 
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Within this library of compounds they furnished nitrogen containing heteroatom 
derivatives 119 and 121 (Figure 1.7).  Unfortunately, these compounds showed the 
poorest MIC values at >88 and >86 respectively.  The four most active members of 
analogue series II are compounds 105, 114, 115 and 116 falling between 
1.1µm/mL<MICMRSA<10µm/mL.  In the tetracyclic cage certain modifications can be 
tolerated without major effects on biological activity.  The data reported has served as a 
guideline for future design and synthesis of any analog program of platensimycin to 
create more potent antibacterial agents.   
 
Figure 1.7 Derivatives containing nitrogen heteroatom  
 
Sintim and co-workers have developed a route to the tetracyclic ketolide of 
platensimycin using a unique synthetic route.34  Using this method have led to their 
investigation of simpler analogues of the natural product.  These analogues include the 
 33 
 
oxazinidinyl platensimycin 122, its methyl ester analogue 123, and a simpler oxazinidinyl 
analogue 124 (Figure 1.8).   
 
Figure 1.8 Platensimycin and novel analogues containing two heteroatoms  
 
The path to oxazinidinyl 122 was achieved through a successful synthesis of tricycle 133 
starting with bis-alkene 126.  Employing a regioselective epoxidation to intermediate 128 
is a key step to the overall route towards tricycle 132 (Scheme1.18).  They have 
fashioned a novel strategy using dynamic ring-closing metathesis and nucleophilic 
addition to a ketone as well as epoxide ring opening to obtain the tricyclic core of 
platensimycin. Following this pathway the Sintim group made other polycyclic motifs 
and found its biological data.  The most potent analogue oxazinidinyl platensimycin 122 
showed a minimal inhibitory concentration (MIC) of 90µg/mL for the bacterial strains 
tested.  Analysis of the methyl ester analogue 123 and the platensimycin analogue with 
the simpler core structure 124 exhibited values greater than 512µg/mL.  The MIC values 
observed further leads to the fact that any modification to the ketolide can have a major 
affect on antibiotic potency indicating how important it is to have the enone present in the 
molecule.    
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Scheme 1.18 Total synthesis of oxazinidinyl platensimycin 
 
A method exploiting the organopalladium cross-coupling reactions were 
implemented by McNulty and co-workers towards sulfonamide analogs.35   Installation of 
a carboxylic group to nitroresorcinol halide 137 was facilitated by palladium complexed 
with 1,3,5,7-tetra-methyl-2,4,8-trioxa-6-phenyl-6-phospha-adamantane (Pd(OAc)2/PA-
Ph).  Reduction of the nitroester 138 followed by subsequent conversion to sulfonamide 
ester 140 led to their series of lipophilic aryl analogues in good yields (Scheme 1.19).   
This route was used to replace the bulky tetracyclic core of platensimycin with the 
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sulfonamide moiety, which can be found in a variety of antibiotics. In six sequential steps 
they have created a set of novel analogues that are currently undergoing biological 
evaluations.     
 
Scheme 1.19 Palladium-mediated carbonylation toward sulfonamide analogues 
 
There has been reported by Lee and co-workers that they have synthesized two 
analogues more potent than platensimycin.36   An efficient and concise route to the parent 
compound has been achieved via intramolecular dipolar cycloaddition of a carbon ylide 
to produce intermediate 142.  Further elaboration of this tricyclic construct has led to the 
derivation of a wide variety of easily accessible analogues (Scheme 1.20).  In vitro 
bioassay studies with the aforementioned compounds verified the substitution of the 15-
methyl group did little to enhance antibacterial activity of the compound.  Interestingly, 
they found analogues 7-phenylplatensimycin 144g and 11-methyl-7-phenylplatensimycin 
144h displayed higher activity than platensimycin against MRSA. 
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Scheme 1.20 Carbonyl ylide cycloaddition route to a series of more potent analogues 
 
With so many research groups generating novel analogues centered only around 
changing the polycyclic ketolide, Manallack and co-workers have recently reported a 
series of simplified molecular mimics of platensimycin.37  This library of compounds 
underwent modifications to both the benzoic acid moiety and tetracyclic enone of the 
parent compound.  These changes still capture the key binding elements observed in 
platensimycin within the FabF active site; however, the new compounds exhibit reduced 
flexibility and molecular weight.  The series of 2-hydroxybenzoic acid derivatives 
designed directly linked the aromatic group to a set of cyclic aliphatic structures.  SAR 
studies were performed on a variety of polycyclic cage-like moieties made by this group 
(Table 1.2).   Additionally, other compounds were synthesized that simplified the highly 
substituted benzoic acid ring to a 3-amino-2-hydroxybenzoic acid.  Based on these 
studies it was found that simplification of platensimycin reduced biological activity.  It 
was imperative that the groups required for activity are the 4-hydroxy group along with 
those necessary for hydrogen bonding to residues close to the binding pocket.   
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Scheme 1.21 Strategy towards semi-rigid compounds 
 
Table 1.2 
Compound R1 R2 MRSA (10 ug/disc) 
147a 
147b 
OH 
H 
 
 
0 
0 
148a 
148b 
OH 
H 
 
 
20 
0 
149a 
149b 
OH 
H 
 
 
0 
0 
150a 
150b 
OH 
H 
 
 
8 
0 
151a 
151b 
OH 
H 
 
 
0 
0 
152a 
152b 
OH 
H 
 
 
0 
21 
153a 
153b 
OH 
H 
 
38 
14 
154a 
154b 
OH 
H 
 
10 
10 
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Summary and Conclusion 
 The connections between natural bioactive molecules and medicines have been 
known for thousands of years.  With increasing pathogen resistance to some existing 
therapeutic agents plus the evolution of new diseases, the continuous efforts of 
researchers has been focused on novel drug candidates.  Medicinal chemists are 
designing novel synthetic routes furthermore enhancing the efficacy and potency of 
natural products through analog development.  A wide range of chemical reactions have 
been responsible for the syntheses of these intricate scaffolds from their simpler 
counterparts.   Oxabicyclic synthons are valuable intermediates derived from the Diels-
Alder reaction to incorporate molecular complexity observed in natural products.   
Combining this reaction with metathesis reorganizations have been utilized quite often 
for the formation of fused polycyclic and spirocyclic structures embedded in various 
complex natural structures.  Implementation of these two key reactions can help in our 
routes towards our desired targets.  Antioxidants have been probed due to their practical 
application as a means to stabilize free radicals in the body which are responsible for 
numerous diseases.  Infectious disease remains a constant nuisance to humanity despite 
the development of so many new antibiotics. The existing analogue programs for the 
antibiotic platensimycin focused on changes to both regions of the molecule; however, it 
is hypothesized that manipulation of the tetracyclic ketolide will have the greatest 
influence on the bioactivity in the enzyme. Hence this lipophilic polycyclic domain has 
been the key focal point of many researchers.    
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CHAPTER 2 
RESULTS/DISCUSSIONS 
In this chapter we will discuss our investigation into the application of new 
synthetic routes towards complex furan containing natural products.  The first section 
will describe the strategies towards phelligridin G using both electrochemical oxidation 
of furyl substituted silyl enol ethers and behavior of oxabicyclic bridged ethers in the 
presence of Grubbs’ olefin metathesis.  The last section describes our route to novel 
analogs of platensimycin using flexible ether-bridged synthons. Exploitation of this 
molecular scaffold made it feasible to develop novel derivatives in a concise and direct 
formal total synthesis. 
Spirocyclic Core of Phelligridin G 
Our retrosynthetic analysis targeted the core domain 104 comprised of the A, B 
and C rings that contains the challenging 2-oxaspiro-[4.4]-octane unit (Scheme 1).  We 
have been interested for some time in developing furan-based methodologies for the 
synthesis of polycyclic systems and felt that phelligridin G offered an excellent target to 
evaluate two strategies we have pursued.  In one path, the presence of the spiro-fused 3-
furanone makes it an attractive target for an electrochemical annulation strategy through 
oxidative cyclization of 156.  We have worked extensively with furan-terminated 
electrochemical oxidative cyclizations and this method has been successful in the 
formation of 5-, 6-, and 7-membered carbocycles.1–4  In a parallel approach to the anodic 
oxidation, a sequential furan Diels-Alder reaction to give 155, followed by a ring opening 
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metathesis/ring closing metathesis (ROM/RCM) process could also deliver the target 
intermediate, a strategy we have recently employed in an approach to cyclopamine.5  
Exploration of both strategies would rely on the same two commercially available 
building blocks 158 and 159.  
 
Scheme 2.1 Retrosynthetic Analysis of Phelligridin G 
 
Currently there are no published syntheses of any member of the phelligridin family of 
natural compounds. 
 
Anodic Oxidation of Silyl Enol Ethers 
The goal of our early studies was to investigate the behavior of silyl enol ethers 
tethered to 2-phenylfuran substrates.   Initial evaluation of the spiro-fused 3-furanone 155 
made it an interesting target through a nontraditional ring annulation methodology. 
Electrochemical methods have usually been examined as a last resort in the oxidative and 
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reductive conversions in organic chemistry.  Previous studies in our research group have 
allowed us to utilize electrochemical oxidations because this particular route is 
uncomplicated, environmentally friendly, and a quick path to some very interesting 
organic compounds.2–4,6  A variety of ring closures have been successfully achieved 
including five-, six-, and seven-membered carbocycles present in many biologically 
active motifs.  For phelligridin G, we have synthesized a series of enol ether 
intermediates to attempt a two-step, conjugate addition/anodic oxidation sequence to gain 
access to the annulated furan moiety.  The commercially available starting materials 2-
furanboronic acid 158 and 3,4-dimethoxy-bromobenzaldehyde 159 were united through 
standard Suzuki cross-coupling with bis(triphenylphosphine)palladium(II) dichloride to 
produce the 2-phenyl-furan derivative 160 in good yield (Scheme 2.2).  The aldehyde was 
homologated with t-butyldimethylsilyl cyanide, followed by reduction of the nitrile group 
in the presence of DIBAL-H to give the protected α-hydroxyaldehyde after hydrolysis 
with dilute sulfuric acid.  The α,β-unsaturated aldehyde underwent smooth Wittig 
olefination to deliver enol ether intermediate 163.  
 45 
 
 Scheme 2.2 Electrooxidative cyclization attempt to the spirocyclic core of phelligridin G 
 
Due to its ease of reactivity, the aldehyde functional group was our target location 
for chemical transformations in order to generate a series of enol ether cyclization 
precursors (Scheme 2.3).  The formerly synthesized 2-furylbenzaldehyde 160 was 
olefinated under standard Wittig conditions with 1-triphenylphosporanylidene-2-
propanone in the presence of nBuLi base.  After methyl ketone 165a was generated and 
purified, the formation of our electron rich silyl enol ether intermediate was attempted.  
Originally our efforts were focused towards conjugate reduction of the carbonyl 
derivative, so we began with the commonly used copper hydride ligand complex known 
as Stryker’s reagent.7  In addition, we contemplated using a copper (I) source in 
conjunction with methyl Grignard to promote a 1,4 addition to the methyl ketone.  
Surprisingly, generation of the enolate anion failed in this particular system only to 
surrender starting enone which made trapping the trimethylsilyl cation impossible.  
Finally, 165b was obtained after successful saturation of the double bond with 
Wilkinson’s rhodium catalyst and enolate trapping with triethylsilane in good yield.8  
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This compound was prepared for electrooxidative cyclization without any further 
purification.   
Most reported oxidative cyclization strategies have been performed using electron 
rich alkenes as a means to generate the radical-cations, however, we wanted to 
investigate the oxidation potential of an appended alkyne to the substrate (Scheme 2.3).  
Our synthetic approach started with the lithiation of the ethoxyacetylene reagent at low 
temperature.  Aldehyde 160 was placed in the cold solution dropwise along with HMPA 
to catalyze the homologation.  The secondary alcohol 166a was obtained and protected 
with TBSCl forming silyl ethynyl ether 166b.  The crude product was readily available 
for oxidative cyclization experimentations.   
Moeller et al. have found highly functionalized silyloxy enol ethers decompose 
during electrochemical oxidations in certain substrates due to instability.  To avoid this 
issue 1,3-dithiane was added to the aldehyde and found to be a suitable radical-cation 
replacement for ring annulations.9,10  Biphenyl 162 was added to a solution of lithiated 
dithiane at -78°C then slowly warmed up to room temperature until complete 
consumption of starting material (Scheme 2.3).  This reaction was monitored by TLC 
resulting in a very clean reaction to give thioether 167.  The aforementioned cyclization 
precursors did not undergo ring annulation during electrolysis.    
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Scheme 2.3 Routes leading toward enol ether intermediates 
 
Being that the initial electron loss in the cyclization precursor is unknown, we have 
developed electronically diverse intermediates 163-167 accessed through the aldehyde 
moiety (Figure 2.1).  These substrates were studied by cyclic voltammetry to resolve this 
issue.  Unfortunately, all attempts to produce the spiro-fused product through anodic 
oxidation failed, producing only complex mixtures of products despite our earlier success 
with similar sytems.11  
Cyclic Voltammetry Studies 
Cyclic voltammetry (CV) was used to determine the oxidation potential of the 
intermediates 163, 164, 165b, 166b, and 167 (Figure 2.1).  Both furan and enol ethers 
have the ability to undergo electrochemical oxidations; therefore, these experiments 
helped identify the initial site of oxidation under our reaction conditions.  A mechanism 
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can be developed from these studies to explain how ring annulation can occur within the 
system.  CV analysis shows which substrate has the lowest oxidation potential; this 
information will indicate the initial loss of electron.  The electrochemical oxidation 
cyclizations attempted were constant current experiments, meaning that potential at the 
surface rises until the first oxidation potential is reached.  Hence if the silyl enol ether 
oxidation potential is lower than the 2-phenylfuran, it can be concluded that the silyl enol 
ether is the preliminary site of oxidation.  Due to the high functionality of our substrates, 
it is possible to have multiple oxidation sites along with single electron transfer leading to 
the formation of an alternate radical-cation. 
 
Figure 2.1 Synthesized enol ether electrooxidative cyclization intermediates 
 
The model studies show that the substrates tested exhibited an irreversible oxidation 
wave pattern in the voltammogram.  In previously published works by Sperry et al., it 
was found that monoalkylated furan has an oxidation potential of 1.3V.2 Our parameters 
for the experiment are dissolving the crude substrate in an “electrolyte” solution and 
placed in a small glass cell.  The environment must be oxygen free, so all reactions were 
done in a glove box.  The voltammogram was set at 200mV/s with continuous scanning 
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until complete oxidation of the material.  As a reference, ferrocene was added to the cell 
along with the silyl enol ether substrates which is commonly used in most CV 
experiments.  The ferrocene shows a duck-like figure which indicates the compound 
undergoes an immediate reduction after being fully oxidized making it reversible.  This 
duck shape is missing from the graph of the organic analytes, so they are designated 
irreversible preventing any reduction once oxidation is complete (See Appendix B).  As 
the current is passed through compound 163, there were three bumps seen on the graph.  
Each bump determines the location of primary electron loss in our given system by 
adding 0.5mA of current.  Initial electron loss occurred at the silyl enol ether at ~1.2V 
with a second oxidation taking place on the furan at 1.3V (previously reported above by 
Sperry et al.). The third and final oxidation site occurs at the methoxy oxygen group 
appended to the alkene at 1.5V.  Further CV analysis showed that doubling the 
concentration of analyte requires the current to be doubled to initiate loss of an electron 
within the system.  The oxidation potential of ether 165b and 166b showed two sites of 
electron transfer for both compounds at 1.1V, 1.3V and 1.0V, 1.3V respectively. The 
ethynl ether required ~1.1mA for electron loss while the triethylsilyl ether was increased 
to ~3.5mA of current to facilitate oxidation.  The addition of ferrocine to the analyte 163 
acts as our reference to verify oxidation is irreversible once complete for our enol ether 
intermediates.  All three compounds proved to be irreversible, a key attribute of all 
organic molecules due to the production of highly reactive intermediate radical-ions that 
undergo further reaction upon formation.   
Further oxidative studies with the above silyl enol ethers were attempted using the 
traditional chemical oxidants cerium(IV)ammonium nitrate (CAN)12 and tris(4-
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bromophenyl)aminium hexachloroantimonate (BAHA)13 which are known to oxidize 
electron-rich olefins, but also proved to be ineffective.  Use of the BAHA reagent had 
previously shown promise in the oxidation of silyl enol ether intermediates; however, this 
alternative method required longer reaction times along with tedious workups.  Despite 
prior success with similar oxidative cyclization, we believe that the presence of additional 
groups with low oxidation potentials such as the dimethoxyphenyl ring and a 2-aryl furan 
leads to significant over oxidation and ultimate destruction of the starting material.  The 
failure to detect any appreciable cyclized material prompted us to explore the alternative 
cycloaddition/metathesis approach to this class of compounds.   
 
Domino Ring-Opening Metathesis/Ring-Closing Metathesis (ROM/RCM) 
A competition study was performed to determine if the presence of additional EWG 
(methoxy groups) played a role in the ability to hinder Diels-Alder adduct formation with 
certain dienophiles.  We examined the potential of two electronically diverse phenylfuran 
scaffolds (Scheme 2.4).  Following a modified procedure, Suzuki palladium cross-
coupling of di- and tetra-substituted bromobenzaldehyde (159 and 168) to 2-furylboronic 
acid 158 we obtained the 2-phenylfurans 160 and 169 in excellent yields.14  
 
Scheme 2.4 Suzuki cross coupling of furan boronic acid 
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The accessibility of the α,β-unsaturated carbonyl allows for easy functional 
transformations  that can lead to the desired annulated spiro-fused intermediate. 
A survey has been conducted on some readily available dienophiles with 2-
phenylfuran substrates 160, 170, and 171.  Each aldehyde was rapidly converted to the 
styrylfuran using Wittig olefination at 0°C in the presence of n-butyllithium base in 
appreciable yields.  Cycloadduct formation is essential for a successful Grubbs’ ring 
opening/ring closing metathesis response due to the increased ring strain of the system.  
The results obtained have led us to find the most reliable dienophiles to move forward 
with our spiro-annulation studies on the ether-bridged intermediates (Table 2.1). For all 
the olefin containing compounds we obtained only starting material which is labeled as 
NR in the table.  The alkyne reagents showed a lot more promise; however, stirring 170 
with the tosyl acetylene produced only starting material and reacting with the di-
substituted arylfuran 171 gave unwanted side products. 
 
Table 2.1 Diels-Alder reaction with 2-phenylfurans 
Substrate Dienophile Temperature Time Yield (%) 
170 
171 
 
 
40-80°C 5-7days NR 
170 
171 
 
25°C 5 days NR 
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170 
 
60-80°C 5 days NR 
171 
170 
 
 
55°C 5 days 47% 
 
 
170 
 
 
 
40°C 24hrs 55% 
170 
 
 
40-50°C 3 days NR 
160 
170 
 
 
55°C 3days 68% 
45% 
160 
170 
 
 
45-55°C 3-5days Decomposition 
  
Toward Oxaspiro-furan Systems 
The value of oxabicyclic building blocks for the preparation of five-membered 
heterocycles has been appreciated for some time.15–17 Our synthesis of the spirocyclic 
core of phelligridin G would be achieved in four steps starting with the previously 
described furyl-benzaldehyde derivative 160 (Scheme 2.5).18 Olefination of the α,β-
unsaturated carbonyl with methyl triphenylphosphonium bromide in the presence of n-
butyl lithium yielded styrylfuran 170.  In order to obtain a suitable precursor for the 
metathesis-driven bond reorganization, thermal cycloaddition to the furan via standard 
Diels-Alder reaction was envisioned.  Usually furan is a highly reactive diene; however, 
this reactivity became highly attenuated in this system due to the presence of the aryl ring 
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in the C2 position.  It has been previously observed that 2-phenylfurans are poor dienes in 
Diels-Alder cycloadditions as a direct result of their high π–conjugation, which is 
destroyed upon formation of the cycloadduct, thus promoting rapid retro-Diels-Alder 
reaction.19 We explored a series of structurally diverse dienophiles based upon 
accessibility and reactivity rates to form the cycloaddition products. 
 
Scheme 2.5 Synthesis of ABC spiroannulated core via Domino ROM/RCM metathesis 
 
Observed in Table 2.1, we found that the sp2-type dienophiles such as n-
methylmaleimide, cyanovinyl acetate, dimethyl fumarate and fumaryl chloride only 
returned unchanged starting materials after days of continuous heating.  Using more 
reactive alkynes seemed promising as we had some success with treating substituted 
furan scaffolds with acetylenic dienophiles in previous studies.5 However, with this 2-
phenylfuran there was no oxabicyclic ether formation observed at moderate temperatures 
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with monofunctionalized alkynes such as tosyl acetylene or methyl propriolate.  At 
higher temperatures, cycloaddition does occur but this is followed by a spontaneous ring-
opening/aromatization process to produce an undesired phenol.  Pleasingly, use of a more 
deactivated alkyne, dimethyl acetylenedicarboxylate (DMAD), under mild thermal 
conditions (rt→40ºC) led to the desired adduct 174 in reasonable yield.  We also 
examined the potential of aldehyde 160 to participate in the [4+2] cycloaddition.  As 
expected, condensation of aldehyde 160 with DMAD required higher temperatures 
(55ºC) as well as longer reaction time owing to the presence of the electron-withdrawing 
group which deactivates the furan ring system.  Ultimately, this reaction did produce the 
adduct 173 in ~50% isolated yield which could be taken on to 174 by olefination. 
Furthermore, small amounts of Michael product 172 occurred as a byproduct.  With the 
key oxabridged intermediate in hand, we were able to attempt the key metathesis 
reaction.  The oxabicyclo adduct 174 undergoes a ring opening/ring closing (ROM/RCM) 
domino type metathesis using Grubbs 2nd generation catalyst 78 to form spiro compound 
175 as a single diastereomer (1H and 13C-NMR) that contains the core structure of 
phelligridin G.  The release of ring-strain in the bridged bicyclic compound is an 
important driving force in these types of reactions and have been increasingly used to 
generate complex natural products.5,20–23   
Toward Oxaspiro-pyran Systems 
In our desire to expand this utility of this methodology, we looked at the highly 
reactive perhalogenated cyclopropenes as cycloaddition partners (Scheme 2.6).  With the 
assistance of these compounds, we have been able to develop building blocks leading to 
the synthesis of several natural products.24,25  It was felt that the cycloaddition of 
 55 
 
perhalocyclopropenes would be more efficient as the initial cycloadduct spontaneously 
rearranges to the ring-expanded system thus preventing the retro-Diels-Alder reaction 
from taking place.  Oxabicyclic[3.2.1]octane 176 was easily prepared in a one-pot 
sequence that involved heating 160 and tetrachlorocyclopropene 6a at 55ºC for 4 days, 
followed by olefination to give 176 without benefit of further purification.  Compound 
170 under similar reaction conditions was much less reactive as the alkene seemed to 
hinder the cycloadduct formation with this particular dienophile.  
 
Scheme 2.6 Expansion of the C-ring of phelligridin G core to form spiro-fused pyran  
 
 The strained ether-bridged seven-membered ring likely undergoes a ring opening of 
the endocyclic double bond followed by closure with the terminal olefin to form the B 
ring of the spiro-fused product.  For oxabicyclic[3.2.1]octane 177, the GII catalyst 78 
was also optimal but heating of the mixture was unnecessary in this system and produce 
the highly functionalized spiro-pyran 178 in moderate overall yield.18     
Efforts Leading to Novel Analogues of Platensimycin 
We have recently developed a novel route to the natural product (+/-)-platensimycin 
utilizing a highly substituted furan and tetrabromocyclopropene (TBCP) to form a 
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flexible oxabicyclic moiety.24  The key feature of this synthetic pathway is that it allows 
for a late stage intramolecular γ-alkylation to form the hydrophobic tetracyclic ketolide 
precursor to the parent compound.  According to work performed by researchers at 
Merck Laboratory, they have developed numerous analogs based upon the alteration of 
the hydrophobic caged region of platensimycin.26  Retrosynthetic analysis focusing on the 
manipulation of the lipophilic moiety will lead to two distinct series of analogues 
(Scheme 2.7).  The first series will analyze ring constriction of the C-ring from a 6-
membered cyclohexenone to the 5-membered cyclopentenone.  A second series will 
require the deletion of the C-ring leading to some simplified acyclic mimics. Both sets of 
derivatives can be generated through the bicyclic intermediate 186, which are prepared 
by a thermal cycloaddition of TBCP and 2,3-disubstituted furan 179.  Of the various 
analogues discussed in Chapter 1, our motifs are structurally unique based on the original 
strategy developed within our research group.  These changes to the hydrophobic cage 
should influence the antibacterial activity.   
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Scheme 2.7 Retrosynthesis of Platensimycin leading to new analogue systems 
      
In our approach furan 179 was reacted with the dienophile 
tetrabromocyclopropene (TBCP) to afford a mixture of tetrabromides 180a and 180b.  
Hydrolysis with silver nitrate and acid promoted deprotection gave a 4:1 mixture of 
regioisomers 183 and 184 in about 96% yield (Scheme 2.8).  It has been observed that the 
presence of the methyl substituent at the bridgehead sterically hinders the attack of the 
water molecule on intermediate 182 leading to the major enone 183.  During this step 
nitric acid is formed in the reaction media causing loss of the silyloxy group leading to 
unprotected alcohols that were easily separable via chromatography.      
 58 
 
O
CH3
OTBS
Br
Br Br
Br
O
CH3
CO2Me
O
Br
Br
OH
CH3
O
TBCP1.LiAlH4, Et2O
AgNO3 (aq)
Acetone
2. TBSCl, Imidazole
178 179
183
O
Br
Br
OTBS
CH3
180a
O
Br
Br
OTBS
CH3
Br Br
Br
Br
O
Br
Br
Br
TBSO
Me
H2O
H2O
O
O
Br
OH
CH3
Br
184
C6H6, 80
oC, 1h
2 steps
-AgBr
4:1 separable
180b
182
 
Scheme 2.8 Synthesis toward dibromoenone intermediates 
 
Protection of the major primary alcohol yielded 185, which simultaneously underwent 
catalytic hydrogenation and debromination with Pd/C under H2 atmosphere in the 
presence of triethylamine base; moreover, further saturation of the alkene at C11-C12 
occurred.  A single diastereomer of keto silyl ether 186 was obtained due to the 
preference for exo addition to the bridged oxabicyclic ring system which establishes the 
three contiguous centers found in the natural product.  Using the keto silyl ether 186, we 
have developed two model studies to test the feasibility of the key intramolecular 
alkylation reaction (Scheme 2.9).  The products attained during ring closure led to the 
inspiration of our distinctive synthetic routes toward an analogue program centered 
around the caged domain of platensimycin.  Ketone 186 was alkylated with allyl iodide in 
the presence of LiHMDS base. Being that the reaction is influenced kinetically, the 
temperature had to remain relatively low to prevent unwanted dialkylated product 
formation.  Controlling the temperature and holding it between -78°C and -10°C, the 
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desired monoalkylated ketone was the major product 187 obtained; however, dialkylated 
product was always observed if temperatures rose to room temperature while stirring.  
Another determining factor that played a key role in our alkylation was the base 
selection; although KHMDS improved the rate of reaction it gave mostly dialkylated 
ketone.  The simple tosylated ketone 188 was obtained by cleavage of the silyl protecting 
group with concentrated acid, HF.pyridine, followed by activation of the primary alcohol 
with tosyl chloride, DMAP, and triethylamine.     
 
Scheme 2.9 
 
Using the oxabicyclic intermediate in our first model system, we exposed the alkylated 
silyl ether 187 to an acid solution of hydrogen fluoride in pyridine followed by tosylation 
to give activated 189.  The allyl ketone 189 was treated with tBuOK in tBuOH solution at 
ambient temperature to give way to the desired caged ether-bridged cycloadduct 190.  A 
key difference in this base promoted intramolecular displacement from our original 
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published sequence is the seco cage formation takes place earlier in the reaction scheme 
as opposed to being the concluding step of the synthetic route.  A modified Wacker 
oxidation procedure offered a route to install the subsequent ketone necessary for a 
cyclocondensation.27–29 The terminal olefin 190 was added to a mixture of copper (II) 
acetate and palladium dichloride in THF under an oxygen atmosphere for 24h.  Standard 
conditions of this oxidation method commonly utilized a stoichiometric amount of CuCl. 
It has been shown that replacing CuCl with Cu(OAc)2 suppressed the acidic hydrolysis of 
the ketone during the catalytic cycle.  Robertson and co-workers found these reaction 
conditions to be the most realiable.30  Continuous bubbling of oxygen into the solution 
yields the desired methyl ketone 191.  Emergence of the α,β-unsaturated carbonyl via 
oxidation of the vinyl group led to the essential diketone for an aldol condensation 
pathway to generate polycyclic ring structures.27  Dropwise addition of tBuOK/tBuOH 
base facilitated the formation of the cyclopentenone C-ring 192 in moderate yields.  
Completion of this novel analogous structure was achieved upon hydrogenation of the 
C4-C9 double bond.  Due to the facial selectivity of the cyclopentenone ring, we 
attempted two different approaches for the saturation of the alkene.  Upon treatment of 
enone 192 with a catalytic amount of Pd/C in a hydrogen atmosphere resulted in a 4:1 
mixture at C9.  Unfortunately, the majority of the hydrogenated product consisted of the 
proton placement at the opposite face of the natural product.  In order to surmount this 
issue, we utilized the diastereoselective hydrogenation method employed by Corey et.al. 
to get the appropriate stereocenter at C-9.31  A high pressure (600psi) hydrogenation 
facilitated by the chiral rhodium catalyst was used to give the desired isomer 193 in a 2:1 
ratio.  Based on NMR experimentation the bridgehead proton shift matched the spectral 
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data of our previous synthesis of platensimycin indicating the correct isomer was the 
major product (Scheme 2.10).   
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Scheme 2.10 Progress towards cyclopentanone analogue 
 
By using a previously published coupling procedure, final conversion to the 
cyclopentanone analogue can be easily derived.  The saturated ketone 193 when treated 
with a bulky base such as LDA or LHMDS leads to enolate formation; this will block the 
top face of the ring and allow for methylation from the less hindered side which generates 
195.  Michael addition using t-butylacrylate generates ester 196.  Trifluoroacetic acid 
promotes cleavage of the t-butyl group providing the acid 197, that can be coupled to the 
aniline group to install the benzoic acid moiety found in the parent natural product.32    
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Scheme 2.11 Proposed Route for Completion of 5-membered ring analogue   
 
Synthesis of Acyclic Analogue Scaffolds 
As outlined in Scheme 2.7 above, platensimycin contains the two distinct 
domains, a polar head group (substituted benzoic acid moiety) and a lipophilic cage, that 
are connected by an amide linker.  We probed the lipophilic group to determine the 
variance in biological activity by adjusting the structure to a more simplified version.  We 
have developed two series of acyclic analogs that we wish to synthesize and then test the 
inhibition activity.  First we synthesized an acyclic ring system in which the oxygen of 
the ketone is displaced by an extended amine chain through reductive amination.33 The 
simplified caged mimic 199 was attained from the alkylation of the activated keto 
tosylate 188 in the presence of base. Following closure of the seco C-ring, reductive 
amination occurs in the company of sodium triacetoxyborohydride to give the nitrogen 
containing intermediate leading to analog 200 (Scheme 2.12).  Titanium isopropyl 
tetraoxide provided a white precipitate upon addition to our homogenous mixture of the 
primary amine and ketone.  Imine formation appeared after about 3h of vigorous stirring.  
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Removal of the methanol left a crude white solid residue which was redissolved in 
dichloromethane, cooled to 0°C, and protonated with the hydride reducing agent to 
furnish amine 200.  The latter step of this stepwise or indirect reductive amination occurs 
rather quickly resulting in a pair of inseparable diastereomers.  It has been reported that 
using sodium triacetoxyborohydride is less toxic and a milder reagent in comparison to 
sodium cyanoborohydride.  The three acetoxy groups stabilize the boron-hydrogen bond 
which can be attributed to the mild reducing properties.34  As we analyze the binding 
properties of the cage domain, a key hydrogen bond interaction occurs between the 
carbonyl oxygen and A309 of FabF.  The amino ester 200 was hydrolyzed under acid 
catalysis with acetic anhydride, pyridine, and a catalytic amount of 4-
dimethylaminopyridine (DMAP) leading to the corresponding acetamide 201.  
Additionally, this acyl group will serve as an adequate protecting group of the secondary 
amine to prevent zwitterionic reactions. Because the C-N peptide bond is stronger than 
the labile hydrogen of the amine, it makes the compound extremely stable to mild acids. 
Cleavage of the t-butyl ester protecting group in the presence of trifluoroacetic acid will 
lead to the exposure of an easily accessible hydroxyl group of acid 202.  Following the 
aforementioned aniline coupling procedures utilized by Corey and co-workers will lead 
to the completion of this acyclic bis-amine compound.   
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Scheme 2.12 Progress towards synthesis of series I acyclic analogs 
The aniline was generated by experimental procedures published by Giannis and 
co-workers using a sequence of steps to form the amino acid (Scheme 2.13).   This 
aromatic ester was constructed starting with the commercially available methy-2,4-
dihydroxy benzoate 203.  The methoxymethyl (MOM) protected benzoic ester 206 was 
assembled in three sequential steps.  Initial nitration of the phenol 203 was accomplished 
with concentrated nitric acid, after which palladium-catalyzed hydrogenation leading to 
the reduction of 204, and final etherification using chloromethyl methyl ether.  Coupling 
of the aniline to carboxylic acid 202 using HATU and triethyl amine followed by 
elimination of all the protecting groups completed our synthesis towards acyclic analog I. 
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Scheme 2.13 Aniline synthesis from Giannis’ Ester and final coupling 
 
Conversion of intermediate 199 to acyclic analog series II can be constructed using 
Wittig olefination to extend the carbon chain through the α,β-unsaturated ketone moiety.  
In order to mimic the binding activity of the natural product within the FabF enzyme, we 
examined a set of commercially available Wittig reagents which had a four carbon chain 
extension containing the carboxylate ester attachment.  Many of them possessed an 
additional ketone β to the ester group which is not observed in platensimycin.  Therefore 
we sought to create a methyl ester which has a single carbonyl encompassed in the amide 
linker.  Generation of this ylide could be easily assembled in situ via a one pot synthesis 
using ordinary Wittig reaction protocols. Utilizing these procedures, methyl 4-
chlorobutyrate can be mixed with triphenylphosphine in the preparation of phosphonium 
salt. Final conversion requires the addition of a strong base such as nBuLi to get the 
 66 
 
desired phosphorus ylide.  Tricyclic ketone 199 can be coupled to the ylide furnishing the 
olefinated intermediate.  The double bond in intermediate 207 will be hydrogenated using 
the Wilkinson’s catalyst followed by subsequent reduction of the ester to carboxylic acid 
intermediate 208 using a strong base such as lithium hydroxide.  Acid 208 will undergo 
aniline coupling according to the procedures used by Corey and co-workers to obtain 
acyclic analogue II (Scheme 2.14).  
 
Scheme 2.14 Proposed synthesis of series II acyclic analogs 
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Conclusions 
We have demonstrated the usefulness of furan as a dependable synthon leading to 
the most complex molecular scaffolds of natural products.  The highly oxygenated 
oxaspirocyclic core of phelligridins G and E presents an interesting synthetic challenge, 
while the potential anticancer and antioxidant properties of the molecules make them 
compelling targets for study.  Moreover, we have investigated two potential furan-based 
routes to the oxaspiro core of those compounds.  Initial attempts to affect an 
electrochemical oxidative cyclization were complicated by facile over-oxidation of the 
products.  An alternative route involving a challenging Diels-Alder cycloaddition with a 
highly substituted 2-styrylfuran, followed by a tandem ring-opening/ring-closing 
(domino) metathesis reaction proved successful.  It was also possible to extend this 
strategy to the higher homolog by using a formal [4+3] cycloaddition reaction with 
tetrachlorocyclopropene.  Current efforts towards the synthesis of phelligridin G based on 
this strategy are ongoing.   
 For the antibiotic platensimycin we have developed novel analogs centered on 
modifying the tetracyclic cage domain by applying a furan-based route with 
tetrabromocyclopropene.  We have replaced the six-membered cyclohexenone with a 
five-membered cyclopentanone C-ring using our previously reported intramolecular 
alkylation strategy to form our caged mimic.  Additionally, we have achieved our second 
goal by simplifying the cage region of the molecule by complete removal of the C-ring. 
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These acyclic derivatives were constructed through displacement of the oxygen of the 
carbonyl using amination and olefination methodologies.  The complete syntheses of 
these uniquely designed compounds are being investigated using the intermediates 
synthesized on the preformed oxabicyclic core.  Once the reaction sequence is complete 
biological evaluations will proceed and be used for comparison to the parent 
platensimycin. 
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CHAPTER 3 
EXPERIMENTAL PROCEDURES 
General 
All reactions were carried out under an inert argon atmosphere with dry solvents under 
anhydrous conditions unless otherwise noted. Commercial grade reagents and solvents 
were used without further purification except as indicated below. Hexanes, 
tetrahydrofuran (THF), diethyl ether (Et2O), and dichloromethane (CH2Cl2) were used 
directly from a Baker cycle-tainer system. Reagents were purchased at the highest 
commercial quality and used without further purification, unless otherwise noted.  Yields 
refer to chromatographically and spectroscopically (1H-NMR) homogenous materials, 
unless otherwise stated. Reactions were monitored by thin layer chromatography (TLC) 
carried out on Whatman silica gel 60 Å precoated plates using UV light as the visualizing 
agent and an acidic mixture of DNP or basic aqueous potassium permanganate (KMnO4) 
and heat as developing agents. Flash chromatography was performed using Baker silica 
gel (60 Å particle size). NMR spectra were recorded on Bruker-500 and 400 instruments 
and calibrated using residual undeuterated solvent as an internal reference (CHCl3 at δ 
7.26 ppm 1H NMR, δ77.1 ppm 13C NMR). The following abbreviations were used to 
explain the multiplicities: s = singlet, d = doublet, t= triplet, q = quartet, m = multiplet, b 
= broad. IR Spectra were recorded on Shimadzu FT-IR 8400 spectrometer. Melting 
points (m.p.) were uncorrected and measured with a Mel-Temp digital melting point 
apparatus. High resolution mass spectra (HRMS) were obtained from the University of 
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Connecticut Mass Spectral Facility by using Direct Analysis in Real Time using a Mass 
Spectrometer: AccuTOF (JEOL). 
 
2-Furan-2-yl-4,5-dimethoxybenzaldehyde (160) 
Commercially available 3, 4-dimethoxy, bromobenzaldehyde 159 (0.5g, 2.04mmol) was 
added to an argon purged 25 ml flask.  Anhydrous THF (10mL) was added followed by 
2-furan boronic acid 158 (2 equiv.), and PdCl2(PPh3)2 (0.1 mol equiv.). Once all the 
reagents were in solution, 2M aqueous solution of Cs2CO3 (3 mol equiv.) was added to 
the flask, immediately added to the preheated oil bath. It was refluxed with vigorous 
stirring for 2-24 hrs. Once the reaction was deemed complete, it was cooled to room 
temperature, quenched with H2O, and diluted with Et2O. The aqueous layer was extracted 
with Et2O (3 x 5mL) and the combined organic layers were washed with brine, dried over 
Na2SO4, and concentrated to give a crude yellow solid. The crude product was purified 
by column chromatography on silica gel (6:1 hexane/ethyl acetate) to yield (95%) 160 as 
a solid. Rf = 0.38; m.p.= 102ºC; IR (KBr, cm-1): υ: 730, 909, 1280, 2255, 3012 1H NMR 
(400MHz CDCl3): δ= 3.96-4.04 (m, 6H), 6.58 (s, 2H), 7.13 (s, 1H), 7.54 (s, 1H), 7.62 (s, 
1H), 10.27 (s, 1H).  13C NMR (126MHz, CDCl3) δ=190.58, 154.46, 153.48, 150.43, 
149.04, 143.47, 128.85, 126.67, 115.40, 111.76, 110.38, 108.83, 77.44, 77.12, 76.80, 
65.76, 56.00; HRMS (DART) calcd for C13H13O4 [M+H]+: 233.0814; found 233.0823.  
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(tert-Butyl-dimethyl-silanyloxy)-2-furan-2’-yl ‘4,5’-dimethoxy-phenyl)-acetonitrile (161)  
To a flame dried flask was added t-butyl dimethylsilylcyanide (0.141g, 1.0mmol), 
potassium cyanide (0.003g, 0.05mmol), and 18-crown-6 (0.053g, 0.4mmol) under an 
argon atmosphere. A solution of aldehyde 160 (0.116g, 0.500mmol) in dry methylene 
chloride (5mL) was added over 30 minutes to the homogenous mixture drop-wise. The 
reaction was stirred vigorously for 24 hrs and monitored by TLC.  Upon completion the 
solvent is removed in vacuo and the crude oily residue was purified by flash 
chromatography using 15% EtOAc in hexanes solution. The silyl cyanide 161 was 
obtained as a pure yellow oil (0.177g, 95% yield).Rf= 0.67; IR(KBr, cm -1) υ: 654, 735, 
908, 2254, 2962, 3012 1H NMR (500MHz CDCl3): δ= 0.02-0.12 (d, J=50Hz, 6H), 0.89 
(s, 9H), 3.93-3.95 (d, J=10Hz, 6H), 5.89 (s, 1H), 6.53 (s, 2H), 7.02 (s, 1H), 7.30 (s,1H), 
7.55 (s, 1H).  13C NMR (126MHz, CDCl3) δ=151.8, 149.5, 147.2, 126.6, 121.8, 119.7, 
111.8, 110.9, 110.1, 108.9, 61.2, 56.2, 25.7, 18.3, -5.1; HRMS (DART) calcd for C20H28 
NO4Si [M+H]+: 374.1788; found 374.1776.  
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(tert-Butyl-dimethyl-silanyloxy)-2-furan-2’-yl‘4,5’-dimethoxy-phenyl)-acetaldehyde (162)  
The silyl cyanide 161 (0.455g, 1.22mmol) was dissolved in dry toluene (4mL) and cooled 
to -78°C. DIBAL (0.868g, 6.1mmol) was added drop-wise to the flask and stir 2 hrs at 
this temp. Once the imine is formed, the reaction was quenched with methanol (2.1mL) 
and warmed up to 0°C. After 2 hrs, 1N H2SO4 (2mL) was added drop-wise to the mixture 
while stirring for 1 hr at this temperature. Add diethyl ether to dilute the reaction and the 
aqueous layer was separated.  Extract aqueous layer with ether (3x 3mL) and collect 
ethereal layer. Wash with brine and dry over Na2SO4, and remove organics in vacuo.  The 
crude oil was purified by flash chromatography using a 10% EtOAc in hexanes solution 
to obtain 162 as pure oil (0.200g, 44% yield).  Rf= 0.49; IR(KBr, cm -1) υ: 732, 913, 
1735, 2934, 2959, 3012 1H NMR (500MHz CDCl3): δ= -0.09-0.02 (d, J=-35Hz, 6H), 
0.87 (s, 9H), 3.91-3.92 (d, J=5, 6H), 5.50 (s, 1H), 6.49-6.61 (dd, J= 10, 5, 2H), 7.07-7.09 
(d, J=10, 2H), 7.51 (s,1H).  13C NMR (126MHz, CDCl3) δ=198.9, 152.3, 149.3, 148.9, 
142.4, 127.2, 122.8, 111.5, 111.2, 110.5, 108.9, 76.2, 56.0, 25.7, 25.7, 18.3, -4.9; HRMS 
(DART) calcd for C20H29O5Si [M+H]+: 377.1784; found 377.1760.  
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Tert-Butyl-[1-(2-furan-2’yl-4’,5’-dimethoxy-phenyl)-3-methoxy-allyloxy]dimethyl-silane 
(163) 
To a stirred solution of dry THF (3mL) was added methoxymethyl triphenylphosphonium 
bromide (0.36g, 0.105mmol) under argon. The homogenous mixture was cooled to 0ºC 
followed by addition of NaOtBu base (2eq.) in one portion. The red-orange suspension 
was stirred about 30 mins as the color persisted under the above temp. A 0.20mM 
solution of 2-furyl benzaldehyde 162 (0.802g, 3.45mmol) in THF was slowly added, and 
the reaction was monitored by TLC at 0ºC. The reaction was quenched with H2O (2mL) 
and diluted with ether (4mL). The aqueous layer was extracted with Et2O, and the 
combined extracts were washed with H2O and Brine then dried over Na2SO4. Removal of 
all organics was done in vacuo to yield crude oily residue as E/Z isomers of 163 (0.020g, 
64%). Rf =0.33; IR (KBr, cm-1): υ: 812, 1278, 1687, 2857, 3233;  1H NMR (500MHz 
CDCl3): δ= -0.11-0.05 (d, J=-30Hz, 6H), 0.86 (s, 9H), 3.48 (s,1H), 3.91-3.92 (d, J=5Hz, 
6H), 4.90-4.94 (m, J = 20Hz, 1H), 5.59-5.60 (d, J =5Hz, 1H), 6.29-6.32 (d, J=15Hz, 1H), 
6.37-6.48 (m, J= 55Hz, 2H), 6.97 (s,1H), 7.22(s,1H), 7.49 (s,1H).  13C NMR (126MHz, 
CDCl3) δ= 153.0, 149.2, 148.8, 147.7, 141.8, 135.7, 120.7, 111.4, 110.9, 109.9, 108.1, 
107.3, 69.1, 56.1, 56.0, 25.9, 18.4, -4.7, -4.7; HRMS (DART) calcd for C22H33O5Si 
[M+H]+: 405.2097; nodetection. 
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(tert-Butyl-dimethyl-silanyloxy)-2[5-tert-butyl-dimethyl-silanyloxymethyl-furan-2-yl]4,5-
dimethoxy-phenyl-acetaldehyde (164a) 
Compound 164b was synthesized using the previous procedure above to assemble enol 
ether 163. Bromo aldehyde 159 dissolved in dry methylene chloride was added dropwise 
to a stirring mixture of TBSCN, 18-crown-6, and KCN.  Coupling occurred with standard 
Suzuki conditions as mentioned above, but the 2-furan boronic acid 158 was replaced 
with the disubstituted 5-formyl-2-furanylboronic acid. After coupling the furaldehyde, 
the carbonyl was reduced to the primary alcohol after that protection using TBSCl to 
generate the aldehyde 164a (0.025g, 50% yield). Rf =0.50 (25% EtOAc in hexanes); IR 
(KBr, cm-1): υ: 838, 1079, 1234, 1414,1509, 2253,2956;  1H NMR (500MHz CDCl3): δ= 
-0.09-0.01 (d, J=-40Hz, 6H), 0.10 (s, 6H), 0.87 (s, 9H), 0.91 (s, 9H), 3.90-3.92 (d, 
J=10Hz, 6H), 4.69 (s, 2H), 5.52-5.53 (d, J =5Hz, 1H), 6.33-6.56 (d, J=5Hz, 2H), 7.09 
(s,2H), 9.61 (s,1H).  13C NMR (126MHz, CDCl3) δ= 191.1,   167.1, 163.5, 156..3, 152..4, 
148.3, 147.9, 129.2, 122.8, 112.6, 110.7, 109.6, 104.3, 98.8, 69.1, 56.3, 56.2, 29.9, 26.1, 
25.8, 18.8, 18.2, -3.4, -4.1, -4.9; HRMS (DART) calcd for C27H44O6Si2 [M+H]+: 
520.2676; 520.2662. 
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2-2-[1-tert-Butyl-dimethyl-silanyloxy)-3-methoxy-allyl]-4,5-dimethoxy-phenyl)-5-tert-
butyl-dimethyl-silanyloxymethyl-furan (164b) 
Employing Wittig olefination we were able to get the methoxy vinyl intermediate.  To a 
stirred solution of dry THF (3mL) was added methoxymethyl triphenylphosphonium 
bromide (0.36g, 0.105mmol) under argon. The homogenous mixture was cooled to 0ºC 
followed by addition of NaOtBu base (2eq.) in one portion. The red-orange suspension 
was stirred about 30 mins as the color persisted under the above temp. A 0.20mM 
solution of 2-furyl benzaldehyde 164a (0.802g, 3.45mmol) in THF was slowly added, 
and the reaction was monitored by TLC at 0ºC. The reaction was quenched with H2O 
(2mL) and diluted with ether (4mL). The aqueous layer was extracted with Et2O, and the 
combined extracts were washed with H2O and Brine then dried over Na2SO4. Removal of 
all organics was done in vacuo to yield an oily residue as E/Z isomers of 164b (0.020g, 
64%). This crude product was readily available to undergo anodic oxidation. 
 
4-(2-Furan-2-yl-4,5-dimethoxy-phenyl)-but-3-en-2-one (165a) 
Dissolve 2-phenylfuran 158 in CH2Cl2 (6mL) followed by 1-triphenylphosphoranylidene-
2-propanone (0.557g, 1.75mmol). The solution was placed into a preheated oil bath 
(41°C) and stirred 48h under reflux monitoring progress by TLC (30%EtOAc in 
hexanes).   Upon completion the solvent was removed in vacuo to get a crude product 
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which was purified by flash chromatography starting with a flushing the column with 
pure hexanes to remove any triphenylphosphine present. The polarity was increased to 
12% EtOAc in hexanes solution while gradually increasing to 15% EtOAc in hexanes to 
get methyl ketone 165a as pure oil (0.115g, 68% yield). [Note: there was some mixed 
product containing desired ketone and unwanted starting aldehyde; therefore needed to 
run a second column for optimum purity].  Rf =0.10(25% EtOAc in hexanes); IR (KBr, 
cm-1): υ: 728, 913, 1136, 1256, 1659, 2243,2938;  1H NMR (500MHz CDCl3): δ= 2.37 
(s,3H), 3.95-3.97 (d, J=10Hz, 6H), 6.39-6.40 (d, J=5Hz, 1H), 6.54-6.58 (d, J=20, 1H), 
6.58-6.61 (d, J=15 Hz, 1H), 7.10 (s,1H), 7.14 (s,1H), 7.56 (m,1H), 7.90-7.94 (d, J= 20Hz, 
1H).  13C NMR (126MHz, CDCl3) δ= 198.6, 151.9, 150.9, 149.1, 142.8, 142.4, 141.0, 
127.4, 125.5, 124.8, 111.9, 110.5, 110.4, 109.2, 56.1, 56.1, 27.2; HRMS (DART) calcd 
for C16H17O4 [M+H]+: 273.1126; found 273.1115.  
[3-(2-furan-2-yl-4,5-dimethoxy-phenyl)-1-methyl-propenyloxy]-trimethyl-silane (165b) 
Silyl ether 165b was obtained using the Wilkinson’s catalyst followed by trapping the 
enolate with Et3SiH.  The methyl ketone 165a (0.057g, 0.209mmol), ClRh(PPh3)3 (2mg, 
0.002mmol), Et3SiH (0.027g, 0.230mmol) were all dissolved in benzene (0.21mL) in a 
pressure vial under argon.  The vial was capped then placed in oil bath at 50°C and 
monitored until deemed complete (~4h).  The benzene was removed to get crude residue 
which could be used for electrochemical oxidation without any further purification [74% 
yield of E/Z isomers (1:0.5)]. Rf =0.30(25% EtOAc in hexanes); IR (KBr, cm-1): υ: 912, 
1278, 1687, 2242, 2957;  1H NMR (500MHz CDCl3): δ= 0.63-0.64 (d, J=-5Hz, 6H), 1.00 
(s, 9H), 1.73 (s,3H), 3.46-3.50 (d, J=20Hz, 6H), 3.75-3.77 (d, J=10Hz, 2H), 4.69 (m, 
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1H), 6.30 (s, 1H), 6.57 (s, 1H), 6.91 (s, 1H), 7.16 (s,1H), 7.32 (s,1H).  13C NMR 
(126MHz, CDCl3) δ= 153.8, 149.6, 148.1, 147.1, 141.0, 131.9, 128.2, 122.8, 113.9, 
111.9, 111.3, 107.7, 107.4, 55.3, 55.2, 30.0, 29.8, 22.4, 6.7, 6.6, 5.9, 5.7; HRMS (DART) 
calcd for C22H32O4Si[M+H]+: 388.5726:[crude sample so no data obtained] 
   
Tert-Butyl-[3-ethoxy-1-(2-furan-2-yl-4,5-dimethoxy-phenyl)-prop-2-ynloxy]-dimethyl-
silane (166b) 
Add ethyl ethynyl ether (0.06g, 0.861mmol) into THF (4mL) at -10°C under an argon 
atmosphere followed by 2.45M n-BuLi (0.37mL, 0.905mmol) solution and stir at 0°C.  
After 30 mins the temperature was cooled to -78°C and a solution of aldehyde 158 
(0.100g, 0.43mmol) mixed with HMPA (0.45mL, 2.54mmol) was added dropwise to the 
flask which was warmed up to 0°C. The reaction was stirred vigorously and monitored by 
TLC in 3:1 Hex:EtOAc solution until deemed complete.  Upon completion the reaction 
was quenched with sat.aq.NH4Cl (3mL).  The mixture was placed in separatory funnel to 
separate the organics followed by extraction of the aqueous layer with EtOAc and the 
combined extracts were washed with H2O and Brine then dried over Na2SO4.  The 
solvent is removed in vacuo and the crude oily residue was purified by flash 
chromatography using 15% EtOAc in hexanes to remove HMPA and any residual 
starting material; next the eluent was increased to 25% EtOAc in hexanes solution to get 
the alkenyl alcohol 166a (0.085g, 65%). [Rf= 0.26 (25% EtOAc in hexanes)] 
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Alcohol 166a (0.085g, 0.281mmol) was placed into round bottom flask dissolving in 
CH2Cl2 (5mL) followed by imidazole (0.077g, 1.12mmol), and DMAP (10 mol%). Cool 
the homogenous mixture to 0°C and add TBSCl (0.085g, 0.562mmol) dropwise while 
stirring vigorously.  Slowly warm up to ambient temperatures and continue stirring until 
silylation is complete monitored by TLC (6:1 Hex:EtOAc).  Filter solution through Celite 
and wash with CH2Cl2.  Remove solvent in vacuo and the crude oily residue was purified 
by flash chromatography using 15% EtOAc in hexanes solution to get silyl ether 166b as 
a pure oil (0.067g, 74% yield).Rf= 0.41; IR(KBr, cm -1) υ: 746, 865, 1244, 1515, 2262, 
2900 1H NMR (500MHz CDCl3): δ= 0.02-0.05 (d, J=15Hz, 6H), 0.87 (s, 9H), 1.30-1.33 
(t, J=10, 5Hz, 3H), 3.92-3.94 (d, J=10Hz, 6H), 4.02-4.06 (m, 2H), 5.78 (s, 1H), 6.49-6.65 
(dd, J=5, 5Hz, 2H), 7.09 (s, 1H), 7.36 (s,1H), 7.49 (s, 1H).  13C NMR (126MHz, CDCl3) 
δ=152.2, 148.9, 148.1, 141.8, 133.8, 120.6, 111.6, 110.2, 109.9, 108.7, 94.4, 74.6, 61.8, 
56.1, 56.0, 40.4, 26.0, 18.5, 14.6,  -4.3, -4.6; HRMS (DART) calcd for C23H33O5Si 
[M+H]+: 417.2097; found 417.2086.  
 
Tert-Butyl-[2-{1,3}dithian-2-ylidene-1-(2-furan-2-yl-4,5-dimethoxy-phenyl)-ethoxy]-
dimethyl-silane (167) 
Peterson olefination conditions were used. Place 1,3-dithiane (0.126g, 0.655mmol) into 
dry THF (1.32mL) cool to -78°C, followed by dropwise addition of  2.0M nBuLi in 
hexanes solution (0.39mL, 0.779mmol). Once all the base was added warm up to 0°C and 
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stir for 5h. After lithiation has successfully occurred, cool the reaction back to -78°C and 
add aldehyde 162 (0.312g, 0.829mmol). Allow to reach room temperature with 
continuous stirring until starting material consumed.  The reaction was quenched with 
H2O, and then poured into separatory funnel for extraction with CH2Cl2.  Brine was 
added to remove emulsion from the cloudy mixture. The combined ethereal layers were 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude residue 
could be purified by flash chromatography using 10% EtOAc in hexanes solution to give 
diastereomers (1:0.5 trans:cis) of dithiane 167. Rf =0.33; IR (KBr, cm-1): υ: 812, 1278, 
1687, 2857, 3233;  1H NMR (500MHz CDCl3): δ= -0.04-0.07 (d, J=15Hz, 6H), 0.88 (s, 
9H), 2.14-2.16 (m,1H), 2.82-2.92 (m, 1H), 3.91-3.94 (d, J=15Hz, 6H), 6.04 (s, 1H), 6.45-
6.50 (m, J= 25Hz, 2H), 6.95 (s,1H), 7.23(s,1H), 7.28-7.29 (d, J=5Hz,1H) 7.53-7.55 (d, 
J=15Hz, 1H). 13C NMR (126MHz, CDCl3) δ= 152.7, 149.2, 147.8, 141.9, 135.1, 129.1, 
129.0, 128.2, 121.2, 117.8, 111.8, 110.0, 108.3, 107.3, 99.4, 67.8, 55.9, 55.8, 29.8, 29.5, 
25.9, 18.2, -4.4, -4.7; HRMS (DART) calcd for C24H34O4S2Si [M+H]+: 479.1746; 
[nodetection: crude sample] 
      
2-(4,4-Dimethoxy-2-vinylphenyl)furan (171) 
To a stirred solution of dry THF (36mL) was added methyl triphenylphosphonium 
bromide (1.52g, 4.32mmol) under argon. The homogenous mixture was cooled to 0ºC 
followed by dropwise addition of a 2.5M solution n-BuLi in hexanes (1.25eq.). The red-
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orange suspension was stirred about 30 mins as the color persisted under the above temp. 
A 0.53mM solution of 2-furyl benzaldehyde 160 (0.802g, 3.45mmol) in THF was slowly 
added, and the reaction was complete at 0ºC after 10-15mins. The reaction was quenched 
with sat. aq.NH4Cl (10mL) and diluted with EtOAc (20mL). The aqueous layer was 
extracted with EtOAc, and the combined extracts were washed with H2O and Brine then 
dried over Na2SO4. Removal of all organics was done in vacuo to yield crude solid 
material, which was purified by silica gel column chromatography (hexane:EtOAc, 10:1) 
to yield olefin 171 as yellow oil (0.568g, 72%). Rf =0.43; IR (KBr, cm-1): υ: 730, 909, 
1266, 2254, 3007 1H NMR (500MHz CDCl3): δ= 3.93-3.95 (d, 6H, J=3.3Hz), 5.24-5.26 
(dd, J = 5, 5Hz, 1H), 5.59-5.62 (d, J =15Hz, 1H), 6.42-6.49 (d, J=35Hz, 2H), 7.99-7.05 
(m, J= 30Hz, 1H), 7.03(s,1H), 7.12(s,1H), 7.48 (s,1H).  13C NMR (126MHz, CDCl3) δ= 
152.64, 148.91, 141.91, 135.98, 128.73, 122.63, 114.14, 111.56, 110.39, 109.39, 56.16, 
56.11; HRMS (DART) calcd for C14H15O3 [M+H]+: 231.1021; found 231.1000. 
 
1-(4’,5’-Dimethoxy-2’vinylphenyl)-7-oxabicyclo[2.2.1]hepta-2,5diene-2,3-dicarboxylic 
acid dimethylester (174) 
Dimethoxy benzylfuran 171 (343mg,1.49mmol) was added to a flame dried vial in 
benzene(0.37mL) to make a 3mM solution followed by addition of DMAD 
(233mg,1.64mmol) at room temperature. The reaction stirred vigorously until everything 
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was in solution then added to preheated oil bath at 40ºC. The reaction was monitored by 
TLC using a 30% EtOAc in hexanes solution. Upon completion the organics were 
removed in vacuo to afford a crude oil, which was purified by silica gel chromatography 
(SiO2,7g; 25%EtOAc in hexanes) to yield cycloadduct 174 as an oil.(0.264g, 55%):Rf 
=0.21; IR (KBr, cm-1): υ: 731, 908, 1268, 2345, 3016; 1H NMR (500MHz CDCl3): δ= 
3.57 (s, 3H), 3.74 (s, 3H), 3.84-3.86 (d, J=10Hz, 6H), 5.14-5.16 (d, J = 10Hz, 1H), 5.50-
5.54 (d, J =20Hz, 1H), 5.75 (s, 1H), 6.92-7.02 (dd, J=15Hz, 15Hz, 1H ), 7.01-7.03 (d, 
J=10Hz, 2H), 7.27-7.28(dd, J=5Hz, 1H), 7.47-7.48 (d, J= 5Hz, 1H).  13C NMR 
(126MHz, CDCl3) δ= 164.9, 162.7, 158.8, 149.4, 149.2, 148.6, 145.2, 144.7, 134.7, 
130.0, 123.6, 114.7, 110.9, 109.4, 97.9, 83.5, 55.9, 52.4; HRMS (DART) calcd for 
C20H21O7 [M+H]+: 373.1287; found 373.1280.  
 
4’5’Dimethoxyspiro[5-oxa-furyl-2,3 di(methoxycarbonyl)-4-vinyl-]-1,1’[1H]indene (175) 
To a solution of oxabicyclic ether 174 (177mg, 0.475mmol) in dry dichloromethane 
(47.5mL) 0.01mM was added a solution of Grubbs 2nd generation catalyst (G-II) 78 
(40mg, 0.0475mmol) in 1ml CH2Cl2 at room temperature. The reaction was stirred 
vigorously at room temperature then placed into preheated oil bath at 35ºC. The reaction 
was monitored by 1Hnmr until deemed complete. After 24hrs of heating, the reaction was 
removed from heat and concentrated to crude brown oil. Purification of the residue by 
flash chromatography using 25% EtOAc in hexanes afforded pure spirocyclic compound 
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175 (.048g, 50%).Rf = 0.21(25% EtOAc in hexanes); IR (KBr, cm-1): υ: 732, 907, 1255, 
2253, 2955; 1H NMR (500MHz CDCl3): δ= 3.56 (s, 3H), 3.81 (s, 3H), 3.87-3.89(d, 
J=10Hz, 6H),  5.28-5.30 (d, J =20Hz, 1H), 5.48-5.51 (d, J=15, 1H), 5.76-5.78 (s,1H) 
5.99-6.04 (m, 1H), 6.16-6.17 (d, J=5.5Hz, 1H),  6.61-6.62 (d, J=5.5Hz, 1H), 6.76(s,1H), 
6.89 (s, 1H).  13C NMR (126MHz, CDCl3) δ= 163.1, 162.3, 150.3, 148.4, 142.9, 136.7, 
136.6, 135.7, 133.7, 128.8, 127.0, 118.1, 107.8, 105.8, 99.38 86.4, 56.5, 56.6, 52.6; 
HRMS (DART) calcd for C20H21O7 [M+H]+: 373.1287; found 373.1283 
 
1-(2’-Formyl-4’,5’dimethoxy-phenyl)-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-
2,3dicarboxylic  acid dimethyl ester (173) 
Dimethoxy-furyl benzaldehyde 160 (343mg,1.49mmol) was added to a flame dried vial 
in benzene(0.37mL) to make a 3mM solution followed by addition of DMAD 
(233mg,1.64mmol) at room temperature. The reaction stirred vigorously until everything 
was in solution then added to preheated oil bath at 50ºC. The reaction was monitored by 
TLC using a 30% EtOAc in hexanes solution. Upon completion the organics were 
removed in vacuo to afford a crude oil, which was purified by silica gel chromatography 
(SiO2,7g; 25%EtOAc in hexanes) to yield cycloadduct 173 as an oil. Diastereomers were 
obtained which could be separated via column chromatography.(0.202g, 50% of desired 
product):Rf =0.085; Rf =0.17; m.p.= 175ºC; IR (KBr, cm-1): υ: 730, 912, 1291, 1684, 
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3024; 1H NMR (500MHz CDCl3): δ= 3.63 (s, 3H), 3.81 (s, 3H), 3.97-3.98 (d, J=5Hz, 
6H), 5.76 (s, 1H), 7.21(s, 1H ), 7.25 (s, 2H), 7.30-7.33(dd, J=5, 5Hz, 1H), 7.45 (s,1H), 
10.03(s, 1H).  13C NMR (126MHz, CDCl3) δ= 190.9, 164.1, 162.7, 156.8, 153.5, 148.9, 
148.3, 144.9, 143.3, 129.9, 126.9, 114.6, 110.3, 96.6, 82.6, 56.2, 56.1, 52.3, 52.2; HRMS 
(DART) calcd for C19H18O8:[M+H]+: 375.1080; found 375.1069. 
 
4’,5’-Dimethoxy-2-(2,3,4,4-tetrachloro-8-oxa-bicyclo[3.2.1]octa-2,6-dien-1-yl-
benzaldehyde (176) 
Dimethoxy furyl- benzaldehyde 160 (0.237mmol) was dissolved in benzene to make a 
2.97M solution at room temperature followed by addition of 
tetrachlorocyclopropene(1eq.). The homogeneous mixture was stirred vigorously and 
heated to 55ºC and stirred for 3-4 days. The reaction was monitored by TLC using a 25% 
EtOAc in hexanes solution. Upon completion the organics were removed in vacuo to 
afford a crude solid, which was purified by flash chromatography (SiO2, 9g; 25%EtOAc 
in hexanes) to yield yellow solid 176. (0.42g, 68%): Rf =0.67; m.p.=175ºC; IR (KBr, cm-
1): υ: 733, 907, 1277, 1516, 2938; 1H NMR (500MHz CDCl3): δ= 3.98-4.07 (d, J= 43Hz, 
6H), 5.46 (s, 1H), 7.00 (s, 1H), 7.30 (s,1H), 7.59 (s,1H), 10.23 (s, 1H). 13C NMR 
(126MHz, CDCl3) δ= 190.1, 153.0, 150.2, 144.7, 138.7, 129.4, 127.9, 122.5, 112.6, 
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110.3, 94.2, 82.6, 75.2, 64.1, 63.3, 56.3, 56.2; HRMS (DART) calcd for C16H13Cl4O4 
[M+H]+: 410.9540; found 410.9540. 
 
2,3,4,4,Tetrachloro-1-(4’,5’dimethoxy-2’-vinyl-phenyl-8oxa-bicyclo[3.2.1]octa-2,6-diene 
(177)  
Cycloadduct 176 (0.237mmol) was olefinated as mentioned above to give crude 
compound 177 which was purified using flash chromatography on silica gel 
(hexane:EtOAc, 20:1) to yield a yellow solid (0.57g, 45%).Rf =0.71; IR (KBr, cm-1): υ: 
731, 908, 2252, 2941, 3014; 1H NMR (500MHz CDCl3): δ= 3.95-3.99(d, J=16Hz, 6H), 
5.18-5.21 (d, J = 12Hz, 1H), 5.39(s, 1H), 5.54-5.57 (d, J = 12Hz, 1H), 6.88-7.00 (dd, 
J=4Hz, dd, J=8Hz, 1H ), 6.93(s, 1H), 6.96 (s, 1H), 7.09 (s,1H), 7.19 (s,1H). 13C NMR 
(126MHz, CDCl3) δ= 150.3, 148.4, 145.2, 137.3, 135.1, 132.7, 120.8, 115.0, 113.5, 
110.0, 95.6, 82.4, 75.5, 64.7, 63.6, 56.2,56.1; HRMS (DART) calcd for C17H15Cl4O3 
[M+H]+: 408.9747; found 408.9767. 
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4’5’Dimethoxy spiro[6-oxa-pyrano-2,3,4,4 tetrachloro-5-vinyl]-1,1’[1H]indene (178) 
Purification of the crude residue 178 by flash chromatography using 25% EtOAc in 
hexanes afforded  pure spiro-fused pyran.  Yield: (0.048g, 48%).Rf = 0.30; IR (KBr, cm-
1): υ: 733, 912, 2324, 2861, 2943; 1H NMR (500MHz CDCl3): δ= 3.90-3.91 (d, J=5Hz, 
6H), 5.07-5.08 (d, J =5Hz, 1H), 5.45-5.47 (d, J=10, 1H), 5.52 (s, 1H) 6.12-6.13 (d, 
J=5Hz, 1H), 6.22-6.28 (m, J=30Hz, 1H),  6.59-6.60 (d, J=5Hz, 1H), 6.81(s,1H), 7.68 (s, 
1H). 13C NMR (126MHz, CDCl3) δ= 150.9, 148.5, 144.9, 137.8, 137.3, 134.3, 132.6, 
131.3, 124.9, 121.2, 111.8, 106.5, 84.0, 70.20, 59.53, 56.6, 56.4; HRMS (DART) calcd 
for C17H15Cl4O3 [M+H]+: 408.9747; found 408.9772.  
O
CH3
CO2Me
O
CH3
OTBS
2. TBSCl, Imidazole,
DMAP, CH2Cl2
0oC
178
1. LAH, THF, 0oC
179
 
Tert-Butyl-dimethyl-(2-methyl-furan-3-ylmethoxy)-silane (179) 
A solution of lithium aluminum hydride (1.8g, 46.4mmol) was added to dry THF (40mL) 
at 0°C, followed by slow addition of methyl 2-methyl-3-furancarboxylate 178 (5.0g, 
35.7mmol). After 15 mins reduction of the methylester was complete, and the reaction is 
quenched via dropwise addition of H2O (1.8mL), 15%NaOH (1.8mL), then H2O (5.4mL).  
Continue stirring for 1h followed by dilution with Et2O (20mL).  Filter the precipitate 
thru funnel and collect the ethereal layers. Dry over MgSO4 (25-30mins) then evaporate 
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most of the ether in vacuo to afford the primary alcohol without any further purification. 
[Note: Compound sits on baseline of TLC plate in 8:1 Hex:EtOAc and is not UV active, 
however illuminates after staining in KMnO4] 
The crude alcohol (35.7mmol) was placed into round bottom flask dissolving in CH2Cl2 
(70mL) followed by imidazole (3.64g, 53.5mmol), and DMAP (0.871g, 7.14mmol). Cool 
the homogenous mixture to 0°C and add TBSCl (5.38g, 35.7mmol) dropwise while 
stirring vigorously.  Slowly warm up to ambient temperatures and continue stirring until 
silylation is complete monitored by TLC (8:1 Hex:EtOAc).  Filter solution through Celite 
and wash with CH2Cl2.  Remove solvent in vacuo and the crude oily residue was purified 
by flash chromatography to furnish furan 179  as a pure clear oil (5.35g, 85% yield) 
(SiO2, 240g, 10% EtOAc in hexanes): Rf = 0.68 (12% EtOAc in hexanes); IR (KBr, cm-
1): υ: 939, 1258, 1629, 2736, 2966; 1H NMR (500MHz CDCl3): δ= 0.08 (s, 6H), 0.91 (s, 
9H), 2.26 (d, J =15.9,Hz, 3H), 4.51 (s 2H), 6.31 (s, 1H), 7.27 (d, 1H) 13C NMR 
(126MHz, CDCl3) δ= 148.2, 140.3, 119.3, 111.2, 57.4, 26.2, 18.6, 11.9, -4.9; HRMS 
(DART) calcd for C12H22O2Si [M+H]+: 225.1311; found 225.1296.  
 
3,4-Dibromo-6-hydroxymethyl-5-methyl-8-oxa-bicyclo[3.2.1]octa-3,6-dien-2-one 
To a flame dried pressure tube was added furan 179 (2.86g, 12.63mmol) and benzene 
(4.2mL, 2.97M) under argon atmosphere. The solution was treated with 
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tetrabromocyclopropene (4.40g, 12.63mmol) at room temperature and the tube was 
sealed.  The tube was placed in an oil bath at room temperature then gradually heated to 
90°C for about 2h.  Upon completion the solution was cooled to room temperature and all 
volatiles were removed in vacuo to give the crude tetrabromide as an inconsequential 
mixture of regioisomers 180a and 180b (1.4:1, 1H NMR). 
The crude mixture (12.63mmol) was dissolved in acetone-H2O (2:1, 64 mL) and treated 
portionwise with AgNO3 (4.29g, 25.26 mmol) over a 30 min period.  The reaction 
mixture was allowed to stir at room temperature for 2h before being poured over solid 
NaHCO3 (4.24g), H2O (100mL), brine (100 mL), dried over Na2SO4, and concentrated to 
give the crude dibromoenone as a mixture of regioisomers (4:1, 1H NMR).  The crude 
material was purified by flash chromatography (SiO2, 150g, 25% EtOAc in hexanes) to 
provide 1.90 g of mixed regioisomers (183+184) and 183 (3.2 g, 80% overall) as a pale 
yellow oil: Rf =  0.24 (25% EtOAc in hexanes); IR (KBr, cm-1): υ: 1049, 1539, 1704, 
3470; 1H NMR (500MHz CDCl3): δ= 1.78 (s, 3H), 1.81 (bs, 1H), 4.39 (ddd, J =15.9, 1.9, 
1.1 Hz, 1H), 4.45 (dt, J=15.8, 1.7Hz, 1H), 5.12 (dt, J= 2.4, 1.2Hz, 1H), 6.27 (dd, J= 4.0, 
2.0Hz, 1H) 13C NMR (126MHz, CDCl3) δ= 183.7, 156.4, 153.2, 123.9, 121.2, 91.3, 85.9,  
58.6, 21.5; HRMS (ESI) calcd for C9H8Br2NaO3 [M+Na]+: 344.8738; found 344.8732.  
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3,4-Dibromo-6-(tert-butyl-dimethyl-silanyloxymethyl)-5-methyl-8-oxa-
bicyclo[3.2.1]octa-3,6-dien-2-one (185) 
Alcohol 183 (2.73g, 8.43 mmol) was dissolved in CH2Cl2 (17mL), cooled to -78°C, and 
treated with 2,6-lutidine (1.47mL, 12.65 mmol). To the cooled solution was added 
TBSOTf (2.13mL, 9.27 mmol) and continued to stir for 1h.  Upon completion, the 
reaction was quenched by addition of H2O and the biphasic mixture was allowed to warm 
up to room temperature.  The layers were separated and the aqueous layer extracted with 
CH2Cl2 (3 x 30mL).  The combined ethereal layers were washed with brine (50mL), dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified by flash 
chromatography (SiO2, 50 g, 10% EtOAC in hexanes) to afford 185 (3.53g, 96%) as a 
yellow oil: Rf =  0.68 (15% EtOAc in hexanes); IR (KBr, cm-1): υ: 839, 1072, 1541, 1710, 
2929, 2953; 1H NMR (500MHz CDCl3): δ= 0.07 (s,3H), 0.08 (s,3H), 0.90 (s,9H), 1.75 (s, 
3H), 4.35 (ddd, J =15.8, 2.0, 1.0 Hz, 1H), 4.40 (dt, J=15.8, 1.8Hz, 1H), 5.10 (dt, J= 2.4, 
1.3Hz, 1H), 6.19 (q, J= 1.9Hz, 1H) 13C NMR (126MHz, CDCl3) δ= 183.8, 156.7, 153.1, 
123.4, 121.1, 91.2, 85.9,  59.1, 25.6, 21.6, 18.3, -5.4, -5.5; HRMS (ESI) calcd for 
C15H23Br2O3 Si [M+H]+: 436.9783; found 436.9778. 
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6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-methyl-8-oxa-bicyclo[3.2.1]octan-2-one(186) 
Dibromoenone 185 (1.01g, 2.30 mmol) was dissolved in EtOAc (4.6mL) and treated with 
Et3N (2.24mL, 16.13 mmol).  To the solution was added 10% Pd/C (1.0g) and the flask 
was evacuated and backfilled with H2 (3 cycles). The reaction mixture was stirred under 
an atmosphere of H2 (balloon) for 4h before being filtered through a pad of SiO2 eluting 
with EtOAc (100mL). The solvent was removed under vacuum and the residue was 
purified by flash chromatography (SiO2, 40g, 10% EtOAc in hexanes) to give ketone 186 
(1.60g, 70%) as a clear oil; Rf = 0.61 (15% EtOAc in hexanes); IR (KBr, cm-1): υ: 838, 
1078, 1095, 1732, 2930, 2955; 1H NMR (500MHz CDCl3): δ= 0.06 (s,3H), 0.89 (s,9H), 
1.43 (s, 3H), 1.50-1.56 (m, 1H), 1.94-2.02 (m, 1H), 2.08-2.15 (m, 1H), 2.19-2.27 (m, 
1H), 2.33-2.54 (m, 3H), 3.66-3.72 (m, 1H), 3.80 (dd, J =10.6, 5.5 Hz, 1H), 4.22 (dd, J 
=8.8 Hz, 1H) 13C NMR (126MHz, CDCl3) δ= 208.2, 81.7, 80.9,  62.8, 48.9, 32.5, 32.1, 
31.7, 26.7, 25.8, 18.2, -5.5, -5.6; HRMS (DART) calcd for C15H29O3 Si [M+H]+: 
285.1886; found 285.1880. 
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3-Allyl-6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-methyl-8-oxa-bicyclo[3.2.1]octan-2-
one (187) 
Ketone 186 (0.078g, 0.274mmol) was dissolved in THF (6mL) and treated with 1.0M 
solution of LHMDS in THF (0.274ml) at -78°C and allowed to stir 30mins under an 
argon atmosphere.  To the solution was added allyl iodide dropwise (0.25mL, 
0.548mmol) and the reaction continued to stir vigorously while being monitored by TLC 
(12% EtOAc in hexanes). Once the reaction was complete, it was quenched with sat. aq. 
NH4Cl (4mL) and diluted with EtOAc (5mL). The biphasic mixture was placed in a 
separatory funnel to remove organic layer.  Extraction of the aqueous layer was 
performed with EtOAc (3x 5mL). The combined ethereal layers were washed with brine 
(5mL), dried over Na2SO4, and concentrated in vacuo The solvent was removed under 
vacuum and the residue was purified by flash chromatography (SiO2, 2g, 10% EtOAc in 
hexanes) to give ketone 187 (0.058g, 67%) as a clear oil; Rf = 0.45 (12% EtOAc in 
hexanes); IR (KBr, cm-1): υ: 838, 1295, 1717, 2931, 2960; 1H NMR (500MHz CDCl3): 
δ= 0.08 (s,6H), 0.91 (s,9H), 1.42 (s, 3H), 1.56-1.60 (dd, J=5, 10Hz, 1H), 1.67-1.72 (m, 
1H), 2.08-2.12 (m, 1H), 2.25-2.27 (m, 2H), 2.58-2.66 (ddd, J=10, 5, 10Hz, 3H), 3.73-
3.86 (dd, J= 15, 15Hz, 2H),  4.23-4.24 (d, J= 5Hz, 1H), 5.05-5.08 (m, 2H), 5.69-5.74 (m, 
1H) 13C NMR (126MHz, CDCl3) δ= 207.8, 135.5, 117.3, 82.8, 80.8, 63.1, 49.2, 41.2, 
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40.2, 34.5, 32.1, 26.5, 26.1, 18.5, -5.3, -5.4; HRMS (DART) calcd for C18H33O3 Si 
[M+H]+: 325.2199; found 325.2197. 
 
3-Allyl-6-hydroxymethyl-5-methyl-8-oxa-bicyclo[3.2.1]octan-2-one (187b) 
Silyl ether 187 (0.197, 0.607mmol) was dissolved in dry THF (3.4mL, 0.18mM) in 
plastic vessel tube at room temperature. The solution was cooled to 0°C following slow 
addition of conc. HF/pyridine (0.16mL, 9.11mmol). After 5mins the ice bath was 
removed allowing the mixture to reach room temperature. The reaction was complete 
after stirring about 1h at this temperature.  Quenching of the reaction was done by 
dropwise addition of the acid to sat.aq. NaHCO3 solution.  The aqueous layer was 
extracted with EtOAc (3 x 4mL) and the organics were collected. Washing the organics 
with brine (4mL), drying over Na2SO4, filtered, and removal of solvent in vacuo led to 
crude alcohol 187b as a clear oil. By TLC the product was slightly above baseline: [Rf= 
0.13(3:1 Hexane:EtOAc solution)]. 
Toluene-4-sulfonic acid 3-allyl-5-methyl-2-oxo-8-oxa-bicyclo[3.2.1]oct-6ylmethylester 
(189) 
The crude alcohol 187b (0.607mmol) obtained was added to dry dichloromethane 
(0.18mM) at room temperature. Sequentially to the solution was added Et3N (0.25mL, 
1.82mmol), DMAP (0.222g, 1.82mmol) and p-toluenesulfonylchloride (0.344g, 
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1.82mmol). Stirring at ambient temperatures and careful monitoring by TLC (25% 
EtOAc in hexanes) showed complete consumption of the starting material after 15mins.  
The mixture was diluted with CH2Cl2 (4mL) and poured into H2O (5mL). The aqueous 
layer was extracted with (3x 5mL) and the combined organics were washed with H2O 
(5mL) and brine (5mL), dried over Na2SO4, filtered, and concentrated in vacuo to give 
crude tosylate 189 as an orange solid: [Rf=0.22 (25%EtOAc in hexanes)]. 
5-Allyl-3-methyl-2-oxa-tricyclo[3.3.1.0]3’,7’nonan-9-one (190) 
To a solution of crude tosylate (0.607mmol) obtained above in dry benzene (12.14mL, 
0.05mM) was slowly added a 1.0M solution of tBuOK in tBuOH (0.79mL) at room 
temperature.  The alkaline solution was stirred for an additional 20 min before the 
addition of sat. aq. NaHCO3( 10mL).  The benzene and tBuOH were removed under 
reduced pressure and the remaining aqueous layer was extracted with EtOAc (3x 10mL). 
The combined organics were washed with brine (10mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude residue was purified by flash chromatography (SiO2, 2 
grams, 10% EtOAc in hexanes) to afford ketone 190 (0.067g, 58%, 3 steps) as oil: Rf= 
0.70 (25% EtOAc in hexanes); IR (KBr, cm-1): υ: 908, 1110, 1372, 1713, 1721, 2253; 1H 
NMR (500MHz CDCl3): δ= 1.52 (s,3H), 1.54-1.55 (d, J=5Hz, 1H), 1.78-1.83 (m, 2H), 
1.92-1.96 (m, 1H), 2.12-2.15 (dd, J=5, 5 Hz, 1H), 2.20-2.26 (m, 1H), 2.34-2.38 (dd, J=5, 
5Hz, 1H), 2.52-2.54 (t, 1H), 4.23-4.24 (d, J=5 Hz, 1H), 5.00-5.03 (m, 2H), 5.73-5.82 (m, 
1H) 13C NMR (126MHz, CDCl3) δ= 209.3, 134.3, 117.6, 87.2, 84.2, 58.2, 53.2, 47.1, 
44.9, 42.9, 35.6, 22.7; HRMS (DART) calcd for C12H17O2 [M+H]+: 193.1229; found 
193.1210. 
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3-Methyl-5-(2-oxo-propyl)-2-oxa-tricyclo[3.3.1.0]3’,7’nonan-9-one(191) 
Oxidation of the terminal vinyl group was done according to the Wacker reaction 
procedure. PdCl2 (15 mmol%)  and Cu(OAc)2 ( 0.126g, 0.634 mmol) were added to 
flame dried flask purged with argon followed by addition of DMF:H2O (6.34 mL) 
solution. The mixture was stirred for 1 hour under an O2 atm.via balloon. Next alkene 
190 (0.122g, 0.634mmol) was dissolved in DMF to make a 0.5mM solution and added to 
the flask dropwise.  The balloon was removed and oxygen was continuously bubbled 
throughout the flask while stirring at room temperature. The reaction was monitored by 
TLC (25%EtOAc in hexanes) until deemed complete.  Upon complete oxidation the 
reaction was quenched with distilled H2O (3mL) and poured into a separatory funnel.  
The aqueous layer was extracted with EtOAc (3x 10mL). The combined organics were 
washed with brine (10mL), dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude residue was purified by flash chromatography (SiO2, 4 grams, 12% EtOAc in 
hexanes) to afford diketone 191 (0.080g, 60%) as an oil. Rf= 0.30 (25% EtOAc in 
hexanes); IR (KBr, cm-1): υ: 906, 1189, 1446, 1727, 2926, 2976; 1H NMR (500MHz 
CDCl3): δ= 1.52 (s,3H), 1.85-1.87 (d, J =10Hz, 2H), 1.89-1.90 (d, J =5Hz, 1H), 1.98-2.03 
(m, 1H), 2.20 (m, 1H), 2.22-2.25 (m, 1H), 2.45 (dd, J =3.5, 5 Hz, 1H), 2.50-2.53 4.22 (d, 
J =15 Hz, 2H), 2.58 (s,1H), 4.25-4.26 (d, J =5 Hz, 1H) 13C NMR (126MHz, CDCl3) δ= 
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208.3, 206.5, 86.8, 83.6, 60.5, 57.3, 53.9, 47.5, 44.4, 44.2, 42.6, 31.4, 22.4, 21.1, 14.3; 
HRMS (DART) calcd for C12H17O3 [M+H]+: 209.1178; found 209.1160. 
 
To the diketone 191 (0.093g, 0.447mmol) in benzene (17.8mL) was added a 1.0M 
solution of t-BuOK/t-BuOH (0.893mL) base at ambient temperature.  The mixture was 
allowed to stir continuously until complete condensation of the starting material which 
was monitored by TLC (25% EtOAc in hexanes).  Addition of sat. aq. NaHCO3 to the 
alkaline solution after 20mins was used to quench the reaction.  The benzene and tBuOH 
were removed under reduced pressure and the remaining aqueous layer was extracted 
with EtOAc (3x 10mL). The combined organics were washed with brine (10mL), dried 
over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by flash 
chromatography (SiO2, 2 grams, 25% EtOAc in hexanes) to afford tetracyclic pentenone 
192 (0.029g, 58%) as oil: Rf= 0.25 (25% EtOAc in hexanes); IR (KBr, cm-1): υ: 917, 
1243, 1631, 1709, 2249, 2969; 1H NMR (500MHz CDCl3): δ= 1.49 (s, 3H), 1.53-1.56 
(m, 1H), 1.83-1.85 (d, J= 10Hz, 1H), 1.95 (s, 1H), 1.96-1.97 (d, J=5 Hz 1H), 2.12-2.14 
(m, 1H), 2.27-2.29 (m, 1H), 2.34-2.36 (d, J =10 Hz, 1H), 2.50-2.53 (d, J =15 Hz, 1H), 
5.02-5.03 (d, J= 5,1H), 5.80 (s, 1H); 13C NMR (126MHz, CDCl3) δ= 180.2, 171.3, 122.7, 
87.1, 76.3,  60.6, 53.7, 52.5, 47.9, 45.2, 42.8, 42.2, 29.9, 22.9, 21.3, 14.4; HRMS 
(DART) calcd for C12H15O2 [M+H]+: 191.1072; found 191.1060. 
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To enone 192 (0.029g, 0.152mmol), [Rh(cod)2]BF4 (0.0123g, 0.030mmol), (4R,5R)-
DIOP (0.0152g, 0.030) were placed in a dry glass vial and dissolved in 1,2-
dichloroethane (3.04mL). The vial was placed in a hydrogenation chamber and purged 
three times (H2) prior to pressurizing the reaction vessel with H2 (600psi). The reaction 
mixture was allowed to stand (no stirring) for 8h before carefully releasing the pressure.  
Because TLC revealed a large amount of an over-reduced by product (Rf= 0.27, 50% 
EtOAc in hexanes), the solution was placed under an atmosphere of argon and solid 
NaHCO3 (0.128g, 1.52mmol) and Dess-Martin periodinane (0.129g, 0.304mmol) were 
added [Note: This over-reduction was seen in our previous reported synthesis of 
platensimycin]. The mixture was stirred at room temperature for 1h before addition of 
sat. aq.NaHCO3 (3mL). The biphasic mixture was stirred for an additional 1h before 
diluting the reaction with CH2Cl2 (5mL).  The layers were separated and the aqueous 
layer extracted with CH2Cl2 (3x5mL). The combined organics were washed with brine 
(10mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was 
purified by flash chromatography (SiO2, 1 gram, 25% EtOAc in hexanes) to afford 
ketone 193 and  its C9 diastereomer  (0.014g, 48%, 2:1 mixture) as an oil: Rf= 0.25 (25% 
EtOAc in hexanes); IR(KBr, cm-1):υ: 912, 1363, 1712, 1740, 2250, 2956; 1H NMR 
(500MHz CDCl3): δ= 1.45 (s, 3H), 1.58 (s, 1H), 1.83-1.85 (d, J= 10Hz, 2H), 1.90-1.92 
(d, J= ,1H), 1.95-1.99 (m, 1H), 2.08-2.09 (s, 1H), 2.22-2.30 (m, 3H), 2.35-2.39 (m, 1H), 
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4.46 (s, 1H); 13C NMR(126MHz,CDCl3) δ=197.1, 87.2, 78.2, 50.6, 49.1, 47.6, 45.4, 
45.2,42.4,39.6,37.2, 23.5;HRMS (ESI) calcd for C12H16O2[M+H]+:193.1229;found 
193.1210. 
O
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6-Hydroxymethyl-5-methyl-8-oxa-bicyclo[3.2.1]octan-2-one (181) 
The ketone 186 (0.348, 1.07mmol) was dissolved in dry THF (6mL, 0.18mM) in plastic 
vessel tube at room temperature. The solution was cooled to 0°C following slow addition 
of conc. HF/pyridine (0.28mL, 16.05mmol). After 5mins the ice bath was removed 
allowing the mixture to reach room temperature. The reaction was complete after stirring 
about 1h at this temperature.  Quenching of the reaction was done by dropwise addition 
of the acid to sat.aq.NaHCO3 solution.  The aqueous layer was extracted with EtOAc (3 x 
5mL) and the organics were collected. Washing the organics with brine (4mL), drying 
over Na2SO4, filtered, and removal of solvent in vacuo led to a crude alcohol 181 as a 
clear oil. By TLC the product was slightly above baseline: [Rf= 0.07(3:1 Hexane:EtOAc 
solution)]. 
Toluene-4-sulfonic acid 3-allyl-5-methyl-2-oxo-8-oxa-bicyclo[3.2.1]oct-6ylmethylester 
(188) 
The crude alcohol (1.07mmol) obtained was added to dry dichloromethane (0.18mM) at 
room temperature. Sequentially to the solution was added Et3N (0.22mL, 1.61mmol), 
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DMAP (0.261g, 1.61mmol) and p-toluenesulfonylchloride (0.304g, 1.61mmol). Stirring 
at ambient temperatures and careful monitoring by TLC (25% EtOAc in hexanes) showed 
complete consumption of the starting material after 2h.  The mixture was diluted with 
CH2Cl2 (4mL) and poured into H2O (5mL). The aqueous layer was extracted with (3x 
5mL) and the combined organics were washed with H2O (5mL) and brine (5mL), dried 
over Na2SO4, filtered, and concentrated in vacuo to give crude tosylate as an orange 
solid. The crude residue was purified by flash chromatography (SiO2, 6 grams, 25% 
EtOAc in hexanes) to afford ketone 188 (0.237g, 68%, 2steps) as oil: Rf= 0.31 (25% 
EtOAc in hexanes); IR (KBr, cm-1): υ: 1035, 1478, 1813, 1959, 3070, 3090; 1H NMR 
(500MHz CDCl3): δ= 1.42 (s,3H), 1.44-1.48 (dd, J=5, 5Hz, 1H), 1.94-1.96 (d, J=10Hz, 
1H), 2.02-2.06 (m, 1H), 2.32-2.44 (m, 3H), 2.48 (s, 3H), 2.51 (m, 1H), 4.11-4.18 (dd, 
J=10, 5Hz, 2H), 4.23-4.25 (d, J=10Hz, 1H), 7.38-7.40 (d, J=10Hz, 2H), 7.80-7.82 (d, 
J=10Hz, 2H), 13C NMR (126MHz, CDCl3) δ= 206.9, 145.5, 132.6, 130.2, 127.9, 81.4, 
80.6, 77.5, 77.2, 77.0, 69.4, 45.9, 32.4, 32.1, 31.6, 26.4, 21.8; HRMS (DART) calcd for 
C16H21O5Si [M+H]+: 325.1110; found 325.1094. 
O
CH3
O
199  
3-Methyl-2-oxa-tricyclo[3.3.1.0]3’,7’nonan-9-one (199) 
To a solution of pure tosylate 188 (0.129g, 0.398mmol) obtained above in dry benzene 
(7.96mL, 0.05mM) was slowly added a 1.0M solution of tBuOK in tBuOH (0.52mL) at 
room temperature.  The alkaline solution was stirred for an additional 20 min before the 
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addition of sat.aq.NaHCO3 (10mL). The benzene and tBuOH were removed under 
reduced pressure and the remaining aqueous layer was extracted with EtOAc (3x 10mL). 
The combined organics were washed with brine (10mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude residue was purified by flash chromatography (SiO2, 2 
grams, 10% EtOAc in hexanes) to afford ketone 199  (0.067g, 68%) as oil: Rf= 0.70 
(25% EtOAc in hexanes); IR (KBr, cm-1): υ: 909, 1031, 1446, 1731, 2225, 2970; 1H 
NMR (500MHz CDCl3): δ= 1.50 (s,3H), 1.72-175 (d, J=15Hz, 1H), 1.81-1.86 (m, 2H), 
2.01 (m, 1H), 2.22 (m, 1H), 2.27-2.30 (d, J=15Hz 1H), 2.50 (s, 1H), 2.76, (s,1H), 4.14 
(s,1H) 13C NMR (126MHz, CDCl3) δ= 209.7, 86.5, 84.2, 52.3, 49.6, 44.2, 42.9, 22.7; 
HRMS (DART) calcd for C9H13O2 [M+H]+: 153.0916; found 153.0892. 
 
3(3-Methyl-2-oxa-tricyclo[3.3.1.0]3’,7’non-9ylamino)propionic acid t-butyl ester (200) 
Tricyclic ketone 199 (0.102g, 0.670mmol) was dissolved in dry MeOH (3.53mL, 
0.19mM) followed by addition of Ti(iOPr)4 (0.250mL, 0.838mmol).  A solution of β-
Alanine-t-Butylester hydrochloride (0.152g, 0.838mmol) in MeOH (1mL) was slowly 
added to the white cloudy mixture. After stirring 1-2h at room temperature, the MeOH 
was removed under reduced pressure and the remaining white solid residue was 
redissolved in CH2Cl2 (2.03mL, 0.33mM). The imine formation was monitored by TLC 
and sat slightly above the baseline. [Rf=0.10 (5% MeOH in CH2Cl2)] The cloudy solution 
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was cooled to 0°C followed by addition of soild NaBH(OAc)3 (0.178g, 0.838mmol) in 
one portion to the round bottom  flask. Warm up the mixture to 25°C after 5 mins of 
stirring until the reduction was complete. Finally quench with H2O (6mL), dilute with 
CH2Cl2, and filter thru Celite.  Extract the aqueous layer with CH2Cl2 (3x 8mL). The 
combined organics were washed with brine (8mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude residue was purified by flash chromatography (SiO2, 
3.0 grams, 5% MeOH in CH2Cl2 ) to afford amine 200 (0.120g, 64%) as yellow solid: 
Rf= 0.6 (10% MeOH in CH2Cl2); IR (KBr, cm-1): υ: 650, 733, 908, 1155, 2253, 2974; 1H 
NMR (500MHz CDCl3): δ= 1.35 (s,3H), 1.39 (s, 9H), 1.52-1.55(dd, J=10, 5Hz, 1H), 
1.57-1.59 (d, J=10 Hz, 2H), 1.88-1.90 (s, J=10Hz, 2H), 2.17-2.19 (m, 2H), 2.32 (s, 1H), 
2.58 (s, 1H), 2.81-2.84 (t, 2H), 3.00 (s, 1H),  3.05-3.06 (d,  J=5 Hz, 2H), 4.40 (s, 1H) 13C 
NMR (126MHz, CDCl3) δ= 170.5, 86.4, 81.4, 58.7, 46.1, 44.2, 42.4, 39.0, 38.4, 36.9, 
28.5, 22.9, 22.5; HRMS (ESI) calcd for C16H27O3 N [M+H]+: 282.2069; found 282.2070 
 
3-Acetyl-(3-Methyl-2-oxa-tricyclo[3.3.1.0]3’,7’non-9-yl)-amino-propionic acid t-butyl 
ester (201) 
Tricyclic amine 200 (0.067g, 0.238mmol) was dissolved in dry CH2Cl2 (1.19mL, 0.2mM) 
followed by addition of pyridine
 
(0.024mL, 0.298mmol), and DMAP (10%mmol).  Once 
everything was in solution Ac2O (0.030mL, 0.298mmol) was added at ambient 
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temperature. The mixture was stirred vigorously for 1h or until complete consumption of 
starting amine (monitored by TLC 5%MeOH in CH2Cl2). Quench with aqueous 
sat.NH4Cl followed by dilution with CH2Cl2 (2.0mL). Extract the aqueous layer with 
CH2Cl2 (3x 5mL). The combined organics were washed with brine (5mL), dried over 
Na2SO4, filtered, and concentrated in vacuo. Amide 201 was obtained in 45% yield as 
yellow oil.  The residue without any further purification was treated with concentrated 
15-20 equiv. of trifluoroacetic acid for hydrolysis to yield crude carboxylic acid 202: Rf= 
0.85 (10% MeOH in CH2Cl2); IR (KBr, cm-1): υ: 735, 1149, 1308, 1646, 1725, 2333, 
2929, 2974; 1H NMR (500MHz CDCl3): δ= 1.25 (s,3H), 1.44 (s, 9H), 1.59-1.62(d, J=15,  
1H), 1.71 (s, 1H), 1.78 (m, 2H), 2.01-2.03 (d, J=10, 2H), 2.14 (s, 3H), 2.28 (s, 1H), 2.43 
(s, 2H), 2.53 (m, 1H),  3.76 (s, 1H), 4.20 (s, 1H) 13C NMR (126MHz, CDCl3) δ= 172.0, 
86.6, 81.2, 79.1, 43.7, 41.2, 39.9, 39.0, 29.8, 28.3, 22.9, 22.6. 
H2,Pd/C
MeO2C
OH
OH
MeO2C
OH
OH
NO2 MeO2C
OH
OH
NH2
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203 204 205
 
Dihydroxy benzoate 203 (3.00g, 17.84mmol) was dissolved in a 2:1mixture of AcOH-
Ac2O solution (36mL, 0.5mM) via ultrasonication.  The mixture was cooled to 0°C and 
HNO3 (1.24g, 19.63mmol) in AcOH (9.8mL) added dropwise over 1 min. Once complete 
allow to warm up to ambient temperature and stir 15 min. Next H2O (46mL) was added 
to the brownish colored mixture forming solid precipitate in the reaction flask.  Filter off 
solids and rinse with small amount of water, then dry under vacuum to obtain a crude 
beige solid. This solid product is not the correct isomer.  Collect the clear brown solution 
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and combined washings, then extract with EtOAc; wash with brine, dry over sodium 
sulfate,filter, and removal of solvents in vacuo provided a crude orange product. This 
compound was found to be the desired regioisomer. Nitro ester 204 was obtained in % 
yield as yellow solid needles upon purification on SiO2 (3:1 then 1:1 Hex:EtOAc 
solution) by flash chromatography. Rf= 0.13  (25% EtOAc in n-hexanes); 1H NMR 
(500MHz CDCl3): δ= 3.98 (s, 3H),  6.62-6.64 (d,  J=5 Hz, 1H), 7.98-8.00 (d,  J=5 Hz, 
1H), 11.19 (s, 1H), 12.87 (s, 1H) 13C NMR (126MHz, CDCl3) δ= 170.1, 160.9, 160.3, 
136.9, 109.5, 53.1.[All data matches up with those reported by Giannis et.al.] 
The nitrobenzoate 204 (0.769g, 3.63mmol) was dissolved in EtOAc (8mL) in a purged 
flask. Next Pd/C (10%mmol) was added and continuously stirred at room temperature 
under hydrogen atmosphere (provided by H2 balloon) for 16h. The reaction was 
monitored by TLC. Once hydrogenation was complete, the mixute was filterd through a 
plug of silica and washed with EtOAc. The organic solvent was removed in vacuo to 
provide the primary amine 205.   
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Silyl enol ether 163  
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Silyl enol ether 166b 
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Enol ether 165b 
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Compound 163 vs. Ferrocine 
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